<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmaceutical interventions for emotionalism after stroke - Allida, S - 2022 | Cochrane Library</title> <meta content="Pharmaceutical interventions for emotionalism after stroke - Allida, S - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003690.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmaceutical interventions for emotionalism after stroke - Allida, S - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003690.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003690.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Pharmaceutical interventions for emotionalism after stroke" name="citation_title"/> <meta content="Sabine Allida" name="citation_author"/> <meta content="The George Institute for Global Health, Faculty of Medicine, University of New South Wales" name="citation_author_institution"/> <meta content="Allan House" name="citation_author"/> <meta content="Leeds Institute of Health Sciences, University of Leeds" name="citation_author_institution"/> <meta content="Maree L Hackett" name="citation_author"/> <meta content="The George Institute for Global Health, Faculty of Medicine, University of New South Wales" name="citation_author_institution"/> <meta content="mhackett@georgeinstitute.org.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD003690.pub5" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/11/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003690.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003690.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003690.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antidepressive Agents [therapeutic use]; Crying [psychology]; Emotions; Pharmaceutical Preparations; Randomized Controlled Trials as Topic; *Stroke [drug therapy, psychology]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003690.pub5&amp;doi=10.1002/14651858.CD003690.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="mV7VuqgF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003690\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003690\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","ko","ms","ja","hr","id","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003690.pub5",title:"Pharmaceutical interventions for emotionalism after stroke",firstPublishedDate:"Nov 17, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003690.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003690.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003690.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003690.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003690.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003690.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003690.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003690.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003690.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003690.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2030 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003690.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#CD003690-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#CD003690-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#CD003690-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#CD003690-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#CD003690-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#CD003690-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#CD003690-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#CD003690-sec-0076"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/appendices#CD003690-sec-0092"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/supinfo/CD003690StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/supinfo/CD003690StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmaceutical interventions for emotionalism after stroke</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/information#CD003690-cr-0004">Sabine Allida</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/information#CD003690-cr-0005">Allan House</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003690.pub5/information#CD003690-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Maree L Hackett</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/information/en#CD003690-sec-0111">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 November 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003690.pub5">https://doi.org/10.1002/14651858.CD003690.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003690-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003690-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003690-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003690-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003690-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003690-abs-0005">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003690-abs-0001" lang="en"> <section id="CD003690-sec-0001"> <h3 class="title" id="CD003690-sec-0001">Background</h3> <p>Antidepressants may be useful in the treatment of abnormal crying associated with stroke. This is an update of a Cochrane Review first published in 2004 and last updated in 2019. </p> </section> <section id="CD003690-sec-0002"> <h3 class="title" id="CD003690-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of pharmaceutical treatment in people with emotionalism after stroke. </p> </section> <section id="CD003690-sec-0003"> <h3 class="title" id="CD003690-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group Register, CENTRAL, MEDLINE, Embase, four other databases, and three trials registers (May 2022). </p> </section> <section id="CD003690-sec-0004"> <h3 class="title" id="CD003690-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs comparing psychotropic medication to placebo in people with stroke and emotionalism (also known as emotional lability, pathological crying or laughing, emotional incontinence, involuntary emotional expression disorder, and pseudobulbar affect). </p> </section> <section id="CD003690-sec-0005"> <h3 class="title" id="CD003690-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials, assessed risk of bias, extracted data from all included trials, and used GRADE to assess the certainty of the body of evidence. We calculated the mean difference (MD) or standardised mean difference (SMD) for continuous data and the risk ratio (RR) for dichotomous data, with 95% confidence intervals (CIs). We assessed heterogeneity using the I<sup>2</sup> statistic. The primary emotionalism measures were the proportion of participants achieving at least a 50% reduction in abnormal emotional behaviour at the end of treatment, improved score on the Center for Neurologic Study ‐ Lability Scale (CNS‐LS) or Clinician Interview‐Based Impression of Change (CIBIC), or diminished tearfulness. </p> </section> <section id="CD003690-sec-0006"> <h3 class="title" id="CD003690-sec-0006">Main results</h3> <p>We did not identify any new trials for this update. We included seven trials with a total of 239 participants. Two trials had a cross‐over design, but outcome data were not available from the first phase (precross‐over) in an appropriate format for inclusion as a parallel randomised controlled trial (RCT). Thus, the results of the review are based on five trials with a total of 213 participants. It is uncertain whether fluoxetine increases the number of people who have a 50% reduction in emotionalism when compared to placebo (risk ratio (RR) 0.26, 95% CI 0.09 to 0.77; P = 0.02; 1 trial, 19 participants) because the certainty of evidence is very low. </p> <p>Sertraline may lead to little to no difference in Center for Neurologic Study ‐ Lability Scale (CNS‐LS) scores and Clinician Interview‐Based Impression of Change (CIBIC) scores when compared to placebo (RR 0.20, 95% CI 0.03 to 1.50; P = 0.12; 1 trial, 28 participants; low‐certainty evidence). Antidepressants probably increase the number of people who experience a reduction in tearfulness (RR 0.32, 95% CI 0.12 to 0.86; P = 0.02; 3 trials, 164 participants; moderate‐certainty evidence). No trials were found that evaluated the impact of other pharmaceutical interventions. </p> <p>Only two trial authors systematically recorded and reported adverse events, resulting in limited data on the potential harms of treatment. Six trials reported death as an adverse event and found no difference between the groups (antidepressants versus placebo) in the number of deaths reported (RR 0.59, 95% CI 0.08 to 4.50; P = 0.61; 172 participants; moderate‐certainty evidence). </p> <p>This review provides very low‐ to moderate‐certainty evidence that antidepressants may reduce the frequency and severity of emotionalism. The included trials were small and had some degree of bias. </p> </section> <section id="CD003690-sec-0007"> <h3 class="title" id="CD003690-sec-0007">Authors' conclusions</h3> <p>Antidepressants may reduce the frequency and severity of crying or laughing episodes when compared to placebo, based on very low‐certainty evidence. Our conclusions must be qualified by several methodological deficiencies in the trials and interpreted with caution despite the effect being very large. The effect does not seem specific to one drug or class of drugs. More reliable data are required before appropriate conclusions can be made about the treatment of post‐stroke emotionalism. Future trialists investigating the effect of antidepressants in people with emotionalism after stroke should consider developing and using a standardised method to diagnose emotionalism, determine severity, and assess change over time; provide treatment for a sufficient duration and follow‐up to better assess rates of relapse or maintenance; and include careful assessment and complete reporting of adverse events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003690-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003690-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003690-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003690-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003690-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003690-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD003690-abs-0010">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003690-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003690-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003690-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003690-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003690-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003690-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003690-abs-0002" lang="en"> <h3>Medicines for emotionalism after stroke</h3> <p><b>Review question</b> </p> <p>To evaluate the benefits and harms of medicine in people with emotionalism after stroke.</p> <p><b>Background</b> </p> <p>Emotionalism often occurs after stroke. Emotionalism means that the person has difficulty controlling their emotional behaviour. After stroke, people may suddenly start crying or, less commonly, laughing for no apparent reason. This is distressing for that particular person and their carers. Antidepressants, known to be helpful in people with depression, may be an effective treatment for emotionalism after stroke, but there have been very few randomised controlled trials (RCTs) in this area. (RCTs are studies in which participants are assigned randomly to 2 or more treatment groups. This is the best way to ensure that groups of participants are similar, and that investigators and participants do not know who is in which group.) </p> <p><b>Search date</b> </p> <p>We identified studies through searches conducted on 26 May 2022.</p> <p><b>Study characteristics</b> </p> <p>We included 7 randomised controlled trials, involving 239 people with emotionalism, in the review, which reported on the use of antidepressants for treating emotionalism. The numbers of people included in the studies ranged from 10 to 92. The mean/median ages ranged from 57.8 years to 73 years. Studies were from Europe (UK: 1; Denmark: 1; Scotland: 1; and Sweden: 1); Asia (South Korea: 1 and Japan: 1); and the USA (1). </p> <p><b>Key results</b> </p> <p>We did not identify any new studies in our search update. We included 7 studies involving 239 people. However, 2 studies were not available in the appropriate format to include in the analysis. Therefore, we included only 5 studies, with 213 people, in our analyses. It is uncertain whether antidepressants affect the number of people with at least a 50% reduction in emotional displays, tearfulness, and scores on the questionnaires that measure uncontrollable laughing or crying, but they had no effect on lability (frequency of mood changes) scores and whether a clinician thought there had been an improvement when compared to placebo. No studies of other types of medicine were found. Six studies reported death and found no differences between those who were on antidepressants and those who were not. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence is moderate to very low, and the results of further research could differ from the results of this review. Our confidence is limited because the included studies were small, and there was no consistency in how emotionalism was measured across the studies. </p> <p><b>Conclusion</b> </p> <p>It is uncertain whether antidepressant medicines reduce outbursts of crying or laughing. More studies with systematic assessment and reporting of unwanted or harmful effects of a treatment are needed to ensure that any benefits outweigh the risks. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003690-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003690-sec-0087"></div> <h3 class="title" id="CD003690-sec-0088">Implications for practice</h3> <section id="CD003690-sec-0088"> <p>Antidepressants may reduce the frequency of emotionalism after stroke. However, there is continued uncertainty about who might benefit the most from treatment amongst those who meet the clinical features indicative of emotionalism. There are no data to guide recommendations about how long people should remain on treatment or what side effects may be expected. Given the limited evidence, clinicians and people who have had a stroke may consider a therapeutic trial of antidepressants when emotionalism is persistent and severe. </p> </section> <h3 class="title" id="CD003690-sec-0089">Implications for research</h3> <section id="CD003690-sec-0089"> <p>We recommend that future trials investigating the effect of antidepressants in people with emotionalism after stroke should: </p> <p> <ul id="CD003690-list-0014"> <li> <p>use a standardised method to diagnose emotionalism, determine severity, and assess change over time: this would assume development of a standard definition of emotionalism; </p> </li> <li> <p>use a standard measure of depression as the major confounder to be considered in analyses;</p> </li> <li> <p>recruit an adequate number of participants so that variables such as 'concomitant depression' and 'time passed between stroke and recruitment' can be controlled; </p> </li> <li> <p>provide treatment for a sufficient duration and follow‐up, so that rates of relapse or maintenance of remission can be assessed; </p> </li> <li> <p>include careful assessment and complete reporting of adverse events;</p> </li> <li> <p>limit the number of outcomes to three or four and report results for all outcomes;</p> </li> <li> <p>make the outcomes relevant to the individual participant by, for example, being clear whether reduction in crying frequency or change in crying behaviour represented a satisfactory outcome for the participant; </p> </li> <li> <p>ensure that the theoretical or biological rationale, or both, and sequential development of interventions follow a recommended framework for development, and if a framework is followed, then it must be reported in the main study publications (<a href="./references#CD003690-bbs2-0094" title="WalkerMF , HoffmannTC , BradyMC , DeanCM , EngJJ , FarrinAJ , et al. Improving the development, monitoring and reporting of stroke rehabilitation research: Consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable. Neurorehabilitation and Neural Repair2017;31(10-11):877-84.">Walker 2017</a>); </p> </li> <li> <p>ensure complete intervention descriptions to increase research usability, replicability, and development of standardised interventions, as an identified priority for the world stroke agenda (<a href="./references#CD003690-bbs2-0094" title="WalkerMF , HoffmannTC , BradyMC , DeanCM , EngJJ , FarrinAJ , et al. Improving the development, monitoring and reporting of stroke rehabilitation research: Consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable. Neurorehabilitation and Neural Repair2017;31(10-11):877-84.">Walker 2017</a>); and </p> </li> <li> <p>adopt an implementation fidelity model or framework at the design stage (<a href="./references#CD003690-bbs2-0094" title="WalkerMF , HoffmannTC , BradyMC , DeanCM , EngJJ , FarrinAJ , et al. Improving the development, monitoring and reporting of stroke rehabilitation research: Consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable. Neurorehabilitation and Neural Repair2017;31(10-11):877-84.">Walker 2017</a>). </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003690-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003690-sec-0008"></div> <div class="table" id="CD003690-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Pharmaceutical interventions compared to placebo for emotionalism after stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Pharmaceutical interventions compared to placebo for emotionalism after stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> emotionalism after stroke<br/><b>Setting:</b> inpatient<br/><b>Intervention:</b> pharmaceutical interventions<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressants</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Emotionalism (primary outcome) </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% reduction in emotionalism</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>777 per 1000<br/>(7 to 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.26<br/>(0.09 to 0.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improved score on Center for Neurologic Study ‐ Lability Scale (CNS‐LS)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>643 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>926 per 1000<br/>(611 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.20<br/>(0.03 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinician Interview‐Based Impression of Change ‐ improved score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>643 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>926 per 1000<br/>(611 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.20<br/>(0.03 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diminished tearfulness</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>329 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>718 per 1000<br/>(425 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.32<br/>(0.12 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Emotionalism: mean scores at end of treatment ‐ Pathological Laughter and Crying Scale</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8.40 lower<br/>(11.56 lower to 5.24 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(High score = worse emotionalism)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Depression: Mean scores at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.82 lower<br/>(2.14 lower to 0.51 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hamilton Depression Rating Scale; Montgomery Åsberg Depression Rating Scale (high score = more depressed) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Cognitive functioning: Mean scores at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 lower<br/>(3.27 lower to 2.67 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mini‐Mental State Examination (low score = cognitive impairment)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Activities of daily living: 1. Mean scores at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.4 lower<br/>(5.22 lower to 2.42 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Johns Hopkins Functioning Inventory (high score = worse function)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Adverse events: 1. death: at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(2 to 92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.59<br/>(0.08 to 4.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; GRADE: Grades of Recommendation, Assessment, Development and Evaluation; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio; SMD: standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the certainty of evidence as &lt; 50 participants in total, and only 1 study contributed to the analysis.<br/><sup>b</sup>We downgraded the certainty of evidence due to imprecision.<br/><sup>c</sup>We downgraded the certainty of evidence as we rated one of the studies at high risk for attrition bias.<br/><sup>d</sup>Heterogeneity is considerable (I<sup>2</sup> statistic = 84%). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003690-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003690-sec-0009"></div> <section id="CD003690-sec-0010"> <h3 class="title" id="CD003690-sec-0010">Description of the condition</h3> <p>Disturbances of emotional behaviour, such as difficulty controlling crying or laughing, are common after stroke (<a href="./references#CD003690-bbs2-0065" title="HouseA , DennisM , MolyneuxA , WarlowC , HawtonK . Emotionalism after stroke. BMJ1989;298(6679):991-4.">House 1989</a>). <a href="./references#CD003690-bbs2-0083" title="PoeckK . Pathophysiology of emotional disorders associated with brain damage. In: VinkenPJ , BruynGW , editors(s). Handbook of Clinical Neurology. Holland: Holland Publishing Co, 1969:343-67.">Poeck 1969</a> distinguished two main types of disturbed emotionality associated with brain lesions: one he called pathological crying and laughing, and the other, emotional lability. The main differences were that in the former, provocation was by non‐emotive or incongruous stimuli and the emotional display was socially abnormal and unstable, while in the latter, emotional behaviour was more socially familiar and provoked by typically emotive stimuli. The terminology is used inconsistently in the literature (<a href="./references#CD003690-bbs2-0043" title="AllmanP . Crying and laughing after brain damage: a confused nomenclature. Journal of Neurology, Neurosurgery, and Psychiatry1989;52(12):1439-40.">Allman 1989</a>), and the evidence to support Poeck's dichotomy is not strong. In order to avoid prejudging the issue, we have preferred a general term for all such disorders of emotionality and have called the problem 'emotionalism': the habit of weakly yielding to emotion (<a href="./references#CD003690-bbs2-0065" title="HouseA , DennisM , MolyneuxA , WarlowC , HawtonK . Emotionalism after stroke. BMJ1989;298(6679):991-4.">House 1989</a>). </p> <p>The essential feature of emotionalism is an increase in emotional behaviour (usually crying, but sometimes laughing) that the person reports as being outside normal control, so that they cry or laugh in situations that would not previously have provoked such behaviour. Onset of episodes is often reported as being more sudden and unpredictable than usual, but even so, most report precipitants, which are usually congruent with their emotional response (<a href="./references#CD003690-bbs2-0065" title="HouseA , DennisM , MolyneuxA , WarlowC , HawtonK . Emotionalism after stroke. BMJ1989;298(6679):991-4.">House 1989</a>). </p> <p>There are other disturbances of emotional behaviour after stroke, especially irritable or anxious behaviours. By convention, however, they are not included in the present category, which is restricted to crying and laughing. Emotionalism is associated with an increase in depressive symptoms. Nonetheless, most people with emotionalism do not have a diagnosable depressive disorder, and many do not have significant depressive symptoms at all (<a href="./references#CD003690-bbs2-0053" title="CalvertT , KnappP , HouseA . Psychological associations with emotionalism after stroke. Journal of Neurology, Neurosurgery and Psychiatry1998;65(6):928-9.">Calvert 1998</a>; <a href="./references#CD003690-bbs2-0067" title="KimJS , Choi-KwonS . Post stroke depression and emotional incontinence. Neurology2000;54(9):1805-10.">Kim 2000</a>). </p> <p>The reported prevalence of emotionalism varies across trials. Results of one systematic review, which included 15 English‐language trials involving 3391 participants, indicated that emotionalism affects about 17% of those who have experienced a strokein the first month, 20% between one and six months, and 12% more than six months after stroke (<a href="./references#CD003690-bbs2-0057" title="GillespieD , CaddenAP , LeesR , WestRM , BroomfieldNM . Prevalence of psuedobulbar affect following stroke: a systematic review and meta-analysis. Journal of Stroke and Cerebrovascular Diseases2016;25(3):688-94.">Gillespie 2016</a>). It tends to decline in frequency and severity over the first year, and a few have persistent severe problems. People with emotionalism describe distress and embarrassment and thereby social avoidance and impaired quality of contact with friends and family. </p> </section> <section id="CD003690-sec-0011"> <h3 class="title" id="CD003690-sec-0011">Description of the intervention</h3> <p>Until recently, there had been no U.S. Food and Drug Administration (FDA)‐approved drug to treat emotionalism. However, there are several classes of drugs consistently used by clinicians in an off‐label manner. These drugs are mainly used to treat various central nervous system conditions, targeting serotonin, monoamine, or dopamine receptors. There are case reports and case series suggesting that disorders of emotionality (variously named and defined) may respond to mirtazapine (<a href="./references#CD003690-bbs2-0068" title="KimSW , ShinIS , KimJM , LimSY , YangSJ , YoonJS . Mirtazapine treatment for pathological laughing and crying after stroke. Clinical Neuropharmacology2005;28(5):249-51.">Kim 2005</a>), imipramine (<a href="./references#CD003690-bbs2-0044" title="AllmanP . Drug treatment of emotionalism following brain damage. Journal of the Royal Society of Medicine1992;85(7):423-4.">Allman 1992a</a>), amitriptyline (<a href="./references#CD003690-bbs2-0088" title="SchifferR , CashJ , HerndonR . Treatment of emotional lability with low dosage tricyclic antidepressants. Psychosomatics1983;24:1094-6.">Schiffer 1983</a>), doxepin (<a href="./references#CD003690-bbs2-0088" title="SchifferR , CashJ , HerndonR . Treatment of emotional lability with low dosage tricyclic antidepressants. Psychosomatics1983;24:1094-6.">Schiffer 1983</a>), nomifensine (<a href="./references#CD003690-bbs2-0087" title="SandykR , GillmanMA . Nomifensine for emotional incontinence in the elderly. Clinical Neuropharmacology1985;8(4):377-8.">Sandyk 1985</a>), fluoxetine (<a href="./references#CD003690-bbs2-0063" title="HangerHC . Emotionalism after stroke. Lancet1993;342(8881):1235-6.">Hanger 1993</a>; <a href="./references#CD003690-bbs2-0079" title="NahasZ , ArlinghausKA , KotrlaKJ , ClearmanRR , GeorgeMS . Rapid response of emotional incontinence to selective serotonin reuptake inhibitor. Journal of Neuropsychiatry and Clinical Neurosciences1998;10:453-5.">Nahas 1998</a>; <a href="./references#CD003690-bbs2-0082" title="PanzerMJ , MellowAM . Antidepressant treatment of pathological laughing or crying in elderly stroke patients. Journal of Geriatric Psychiatry and Neurology1992;5(4):195-9.">Panzer 1992</a>; <a href="./references#CD003690-bbs2-0091" title="SloanRL , BrownKW , PentlandB . Fluoxetine as a treatment for emotional lability after brain injury. Brain Injury1992;6(4):315-9.">Sloan 1992</a>), sertraline (<a href="./references#CD003690-bbs2-0050" title="BenedekD , PetersonKA . Sertraline for treatment of pathological crying. American Journal of Psychiatry1995;152(6):953-4.">Benedek 1995</a>; <a href="./references#CD003690-bbs2-0078" title="MukandJ , KaplanM , SennoRG , BishopDS . Pathological crying and laughing: treatment with sertraline. Archives of Physical Medicine and Rehabilitation1996;77(12):1309-11.">Mukand 1996</a>; <a href="./references#CD003690-bbs2-0029" title="MullerU , MuraiT , Bauer-WittmundT , CramonDY . Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Injury1999;13(10):805-11. ">Muller 1999</a>; <a href="./references#CD003690-bbs2-0079" title="NahasZ , ArlinghausKA , KotrlaKJ , ClearmanRR , GeorgeMS . Rapid response of emotional incontinence to selective serotonin reuptake inhibitor. Journal of Neuropsychiatry and Clinical Neurosciences1998;10:453-5.">Nahas 1998</a>; <a href="./references#CD003690-bbs2-0093" title="TanI , DorevitchM . Emotional incontinence: a dramatic response to paroxetine. Australian and New Zealand Journal of Medicine1996;26(6):844.">Tan 1996</a>), paroxetine (<a href="./references#CD003690-bbs2-0029" title="MullerU , MuraiT , Bauer-WittmundT , CramonDY . Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Injury1999;13(10):805-11. ">Muller 1999</a>), and also to lithium (<a href="./references#CD003690-bbs2-0074" title="MasseyE , LoweS . Lithium carbonate in pseudobulbar palsy. Annals of Neurology1981;9(1):97.">Massey 1981</a>), L‐dopa (<a href="./references#CD003690-bbs2-0040" title="UdakaF , YamaoS , NagataH , NakamuraS , KameyamaM . Pathologic laughing and crying treated with levodopa. Archives of Neurology1984;41(10):1095-6. ">Udaka 1984</a>; <a href="./references#CD003690-bbs2-0095" title="WolfJ , SantanaH , ThorpyM . Treatment of 'emotional incontinence' with levodopa. Neurology1997;29:1935-6.">Wolf 1997</a>), and venlafaxine (<a href="./references#CD003690-bbs2-0092" title="SmithAG , Montealegre-OrjuelaM , DouglasJE , JenkisEA . Venlafaxine for pathological crying after stroke. Journal of Clinical Psychiatry2003;64(6):731-2.">Smith 2003</a>). </p> </section> <section id="CD003690-sec-0012"> <h3 class="title" id="CD003690-sec-0012">How the intervention might work</h3> <p>Classic tricyclic antidepressants commonly used to treat emotionalism are thought to block the reuptake of monoamine neurotransmitters, such as serotonin and norepinephrine. Selective serotonin reuptake inhibitors (SSRIs) only reduce the reuptake of serotonin, which in turn increases serotonin activity, and have little effect on other neurotransmitters, such as norepinephrine. However, the effect of these drugs on the disorder of emotionality remains unclear. It does not appear to be the result of a simple antidepressant action, although amelioration of co‐existing depression, which is exacerbating the emotionalism, may be the mechanism of action for some. Recovery occurs in people without a depressive disorder; at times, it occurs in a dramatic fashion, within 24 to 48 hours of starting a low dose, and abnormal laughter may also respond to treatment (<a href="./references#CD003690-bbs2-0071" title="LauterbachE , SchweriM . Amelioration of pseudobulbar affect by fluoxetine. Journal of Clinical Psychopharmacology1991;11:392-3.">Lauterbach 1991</a>; <a href="./references#CD003690-bbs2-0088" title="SchifferR , CashJ , HerndonR . Treatment of emotional lability with low dosage tricyclic antidepressants. Psychosomatics1983;24:1094-6.">Schiffer 1983</a>). There are case reports suggesting that withdrawal of antidepressants leads to re‐emergence of emotionalism, while reinstatement leads to resolution (<a href="./references#CD003690-bbs2-0088" title="SchifferR , CashJ , HerndonR . Treatment of emotional lability with low dosage tricyclic antidepressants. Psychosomatics1983;24:1094-6.">Schiffer 1983</a>; <a href="./references#CD003690-bbs2-0090" title="SeligerGM , HornsteinA . Serotonin, fluoxetine, and pseudobulbar affect. Neurology1989;39(10):1400.">Seliger 1989</a>). However, drug treatment is not always effective and may be complicated by common unacceptable side effects. We have been able to find two case reports of psychological therapy (<a href="./references#CD003690-bbs2-0051" title='BrookshireR . Control of "involuntary" crying behaviour emitted by a multiple sclerosis patient. Journal of Communication Disorders1970;3(3):171-6.'>Brookshire 1970</a>; <a href="./references#CD003690-bbs2-0086" title="SaccoS , SaràM , PistoiaF , ConsonM , AlbertiniG , CaroleiA . Management of pathologic laughter and crying in patients with locked-in syndrome: a report of 4 cases. Archives Physical Medicine and Rehabilitation2008;89(4):775-8.">Sacco 2008</a>). </p> </section> <section id="CD003690-sec-0013"> <h3 class="title" id="CD003690-sec-0013">Why it is important to do this review</h3> <p>Emotionalism is an under‐recognised and under‐treated condition that adversely affects individuals post‐stroke worldwide. Treatment options include the off‐label use of a range of antidepressants. However, there are uncertainties surrounding the benefits versus the risks associated with their use. We undertook a systematic review of all randomised controlled trials (RCTs) and quasi‐RCTs (published) of pharmaceutical agents for the treatment of emotionalism associated with stroke. We did not find any RCTs evaluating non‐drug (psychological) interventions; we will consider any future trials in this area in a separate review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003690-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003690-sec-0014"></div> <p>To evaluate the benefits and harms of pharmaceutical treatment in people with emotionalism after stroke. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003690-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003690-sec-0015"></div> <section id="CD003690-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003690-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered all relevant randomised controlled trials (RCTs) in people with a clinical diagnosis of stroke where a pharmaceutical agent used specifically for the treatment of emotionalism was compared with placebo. We excluded trials in which the allocation to treatment or placebo was not random. We excluded trials that compared two or more antidepressant drugs but did not include a placebo group. We identified RCTs and cross‐over trials in all languages. There was no restriction on eligibility of RCTs on the basis of sample size, duration of follow‐up, or publication status. </p> <p>When we found trials that met all criteria for inclusion but did not present any outcome data (and such data were not available from the authors) and could therefore not contribute to any pooled estimate of effect, we regarded these trials as 'dropouts' rather than ineligible, and they are listed in <a href="#CD003690-tbl-0002">Table 1</a> to indicate that we did not overlook these trials. </p> <div class="table" id="CD003690-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of 'dropout' studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Methods</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003690-bbs2-0008" title="AizawaT , KaseM , KutsuzawaT , HasegawaT , SekimotoH , OmaeT . Clinical evaluation on the effect of cyclandelate in the treatment of cerebrovascular diseases: double-blind comparative placebo-controlled clinical study with cinnarizine as a basic treatment. Rinsho Hyoka1977;5(3):659-86. ">Aizawa 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study design: randomised, parallel design<br/>Number of arms: 2 </p> <p>Arm 1: cyclandelate 900 mg/day + cinnarizine 75 mg/day</p> <p>Arm 2: placebo + cinnarizine 75 mg/day<br/>Analysis: per protocol<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geographical location: Japan</p> <p>Setting: 50 institutes across Japan</p> <p>Number of participants: 378</p> <p>Diagnosis: stroke over 1 month ago</p> <p>Inclusion criteria: 1) inpatients and outpatients who had cerebral infarct, intracranial bleeding, transient cerebral ischaemia, and cerebral arteriosclerosis </p> <p>Exclusion criteria: 1) expectant mothers; 2) with glaucoma, and 3) severe concomitant diseases </p> <p>Age: overall mean age not reported</p> <p>Number of participants included in Arm 1: 188 (68% men, age details unclear)</p> <p>Numbers of participants included in Arm 2: 190 (68% men, age details unclear)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm 1: cyclandelate 900 mg/day and cinnarizine 75 mg/day</p> <p>Arm 2: matched placebo and cinnarizine 75 mg/day</p> <p>Duration: treatment continued for 4 weeks<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD003690-list-0001"> <li> <p>Global improvement rating</p> </li> <li> <p>Improvement rating of subjective symptoms</p> </li> <li> <p>Improvement rating of psychiatric symptoms</p> </li> <li> <p>Improvement rating of neurological symptoms</p> </li> <li> <p>Global utility rating</p> </li> <li> <p>Overall safety rating</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to use: all data (data not presented by 'emotionalism at baseline', unable to exclude people with cerebral arteriosclerosis and transient ischaemic attack) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003690-bbs2-0033" title="OhtomoE , KutsuzawaT , ArakiG , HiraiS , TerashiA , KuzuyaF , et al. Clinical usefulness of tiapride on psychiatric symptoms caused by cerebrovascular disorders: a multi-center double-blind study in comparison with inactive placebo. Rinsho Hyoka1985;13(2):295-332. ">Ohtomo 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study design: randomised, parallel design<br/>Number of arms: 2 </p> <p>Arm 1: tiapride 75 mg/day for 1 week, dose escalation to 150 mg to 225 mg/day for 5 weeks according to clinical response </p> <p>Arm 2: placebo + cinnarizine 75 mg/day<br/>Analysis: per protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geographical location: Japan</p> <p>Setting: unclear</p> <p>Number of participants: 188</p> <p>Diagnosis: cerebral haemorrhage, subarachnoid haemorrhage, cerebral infarction, cerebral apoplexy sequelae, cerebral arteriosclerosis </p> <p>Inclusion criteria: 1) people with cerebral arteriosclerosis</p> <p>Exclusion criteria: 1) severe aphasia, 2) severe dementia, 3) drug dependence, 4) inadequate conditions for the study </p> <p>Age: overall mean age not reported</p> <p>Number of participants included in Arm 1: 141 (54% men, age details unclear)</p> <p>Number of participants included in Arm 2: 147 (61% men, age details unclear)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm 1: tiapride 75 mg/day for 1 week, dose escalation to 150 mg to 225 mg/day for 5 weeks according to clinical response </p> <p>Arm 2: matched placebo</p> <p>Duration: treatment continued for 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD003690-list-0002"> <li> <p>Severity of psychiatric symptoms</p> </li> <li> <p>Activities of daily living</p> </li> <li> <p>Somatic complaints</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to use: all data (data not presented by 'emotionalism at baseline', unable to exclude people with cerebral arteriosclerosis) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003690-bbs2-0024" title="KimJS , LeeEJ , ChangDI , ParkJH , AhnSH , ChaJK , et al. The efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry2017;4(1):33-41. NCT01278498. The preventive effect of escitalopram on depression and related emotional disorders in acute stroke patients. clinicaltrials.gov/ct2/show/NCT01278498 (first received 19 January 2011). ">Kim 2017b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study design: randomised, parallel design<br/>Number of arms: 2 </p> <p>Arm 1: escitalopram 10 mg/day</p> <p>Arm 2: placebo<br/>Analysis: per protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geographical location: South Korea</p> <p>Setting: 17 hospitals across South Korea</p> <p>Number of participants: 478</p> <p>Diagnosis: stroke, had an acute ischaemic stroke or intracerebral haemorrhage within the previous 21 days (confirmed by MRI or CT) </p> <p>Inclusion criteria: 1) &gt; 20 years, 2) had an acute ischaemic stroke or intracerebral haemorrhage within the previous 21 days (confirmed by MRI or CT), 3) modified Rankin Scale score &gt; 2 </p> <p>Exclusion criteria: 1) history of diagnosed depression or other psychiatric diseases before the index stroke; 2) severe dementia, 3) aphasia, 4) exhibited strong suicidal thoughts </p> <p>Age: overall mean age not reported</p> <p>Number of participants included in Arm 1: 210 (57% men, mean age 64 (13) years</p> <p>Number of participants included in Arm 2: 195 (65% men, mean age 64 (12) years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm 1: escitalopram 10 mg/day<br/>Arm 2: matched placebo </p> <p>Duration: 12 weeks<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcomes:</p> <p> <ul id="CD003690-list-0003"> <li> <p>Occurrence of moderate or severe depressive symptoms</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD003690-list-0004"> <li> <p>Occurrence of emotional incontinence (Kim's criteria)</p> </li> <li> <p>Anger proneness (modified Spielberger Trait Anger Scale/ National Institutes of Health Stroke Scale scores) </p> </li> <li> <p>Modified Rankin Scale</p> </li> <li> <p>Barthel Index</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to use: all data (data presented by 'emotionalism at baseline' 1 month post‐treatment)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CT: computerised tomography<br/>MRI: magnetic resonance imaging </p> </div> </div> </section> <section id="CD003690-sec-0018"> <h4 class="title">Types of participants</h4> <p>All participants had to have established emotionalism at the time of entry into the trial. The essential feature of emotionalism is an increase in emotional behaviour (usually crying, but sometimes laughing) that the person reports as being outside normal control, so that they cry or laugh in situations that would not previously have provoked such behaviour. Onset of episodes is often reported as being more sudden and unpredictable than usual, but even so, most people report precipitants, which are usually congruent with their emotional response. </p> <p>We included all participants with a confirmed history of stroke, at any stage after onset, where there was an explicit intention to provide a pharmacological agent to treat emotionalism associated with stroke. We defined stroke according to standard clinical criteria: the criteria included cerebral infarction, intracerebral haemorrhage, and uncertain pathological subtypes, but excluded subarachnoid haemorrhage, which has a different natural history and management strategy to other stroke subtypes. </p> <p>There were no restrictions on the basis of age, sex, or other characteristics. We excluded trials that included mixed populations (such as stroke and head injury or other central nervous system disorders) unless we could identify separate results for those with stroke. We included people with a diagnosed mood disorder or a mood score above the standard cut‐off scores at baseline, provided it was clear that they also met criteria for emotionalism. We excluded those who were being treated primarily for a stroke‐associated pain syndrome or for stroke‐associated depression, even if emotionalism was measured as a secondary (post‐hoc) outcome. </p> </section> <section id="CD003690-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included any trial that attempted to evaluate a comparison between a pharmacological agent and placebo for the treatment of emotionalism following stroke. Specific pharmacological agents that we considered included the following: tricyclic antidepressants (e.g. nortriptyline, imipramine, and clomipramine), selective serotonin reuptake inhibitors (SSRIs) (e.g. fluvoxamine, fluoxetine, citalopram, sertraline, and paroxetine), monoamine oxidase inhibitors (MAOIs) (e.g. moclobemide), and other antidepressant medications. We found no trials of psychostimulants (e.g. methylphenidate), mood stabilisers (e.g. lithium), benzodiazepines, or combined preparations. We will include future trials of psychostimulants but will analyse them separately. </p> </section> <section id="CD003690-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD003690-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>Emotionalism: despite widespread acknowledgement of the importance of the problem, there is no widely accepted standardised set of diagnostic criteria for emotionalism. The primary endpoint emotionalism measures were as follows: </p> <p> <ul id="CD003690-list-0005"> <li> <p>The proportion of participants achieving at least a 50% reduction in abnormal emotional behaviour at the end of treatment. </p> </li> <li> <p>Improved score on the Center for Neurologic Study ‐ Lability Scale (CNS‐LS) (<a href="./references#CD003690-bbs2-0077" title="MooreS , GreshamL , BrombergM , KasarkisE , SmithR . A self-report measure of emotional lability. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):89-93.">Moore 1997</a>). </p> </li> <li> <p>Improved score on the Testing Emotionalism After Recent Stroke – Questionnaire (TEARS‐Q) (<a href="./references#CD003690-bbs2-0052" title="BroomfieldNM , WestR , HouseA , MunyombweT , BarberM , GraceyF , et al. Psychometric evaluation of a newly developed measure of emotionalism after stroke (TEARS-Q). Clinical Rehabilitation2021;35(6):894-903.">Broomfield 2021</a>). </p> </li> <li> <p>Clinician Interview‐Based Impression of Change (CIBIC) (<a href="./references#CD003690-bbs2-0070" title="KnopmanD , KnappMJ , GraconSI , DavisCS . The Clinician Based Impression (CIBI): a clinician’s global change rating scale in Alzheimer’s disease. Neurology1994;44:2315–21.">Knopman 1994</a>). </p> </li> <li> <p>Diminished tearfulness.</p> </li> </ul> </p> </section> <section id="CD003690-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003690-list-0006"> <li> <p>Emotionalism: mean scores at end of treatment. There are a number of measures reported in the published literature (<a href="./references#CD003690-bbs2-0045" title="AllmanP , MarshallM , HopeA , FairburnC . Emotionalism following stroke: development and reliability of a semi-structured interview. International Journal of Methods in Psychiatric Research1992;2:125-31.">Allman 1992b</a>; <a href="./references#CD003690-bbs2-0072" title='LawsonJR , MacleodRD . The use of imipramine ("Tofranil") and other psychotropic drugs in organic emotionalism. British Journal of Psychiatry1969;115:281-5.'>Lawson 1969</a>; <a href="./references#CD003690-bbs2-0077" title="MooreS , GreshamL , BrombergM , KasarkisE , SmithR . A self-report measure of emotional lability. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):89-93.">Moore 1997</a>; <a href="./references#CD003690-bbs2-0080" title="Newsom-DavisI , AbrahamS , GoldsteinL , LeighP . The emotional lability questionnaire: a measure of emotional lability in amyotrophic lateral sclerosis. Journal of the Neurological Sciences1999;169(1-2):22-5.">Newsom‐Davis 1999</a>; <a href="./references#CD003690-bbs2-0085" title="RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93.">Robinson 1993a</a>), but similar to frequency of emotional behaviour, there is no widely accepted standardised measure of severity of emotionalism that could be used to measure this outcome as a continuous variable </p> </li> <li> <p>Depression: mean scores at end of treatment</p> </li> <li> <p>Depression: average change in scores between baseline and end of treatment. Depression as measured on scales such as the Hamilton Depression Rating Scale (HDRS) (<a href="./references#CD003690-bbs2-0062" title="HamiltonM . Rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry1960;23:56-62.">Hamilton 1960</a>), Montgomery Åsberg Depression Rating Scale (MADRS) (<a href="./references#CD003690-bbs2-0076" title="MontgomerySA , AsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382-9.">Montgomery 1979</a>), Geriatric Depression Scale (GDS) (<a href="./references#CD003690-bbs2-0060" title="GompertzP , PoundP , EbrahimS . The reliability of stroke outcome measurement. Clinical Rehabilitation1993;7(4):290-6.">Gompertz 1993</a>), Beck Depression Inventory (BDI) (<a href="./references#CD003690-bbs2-0049" title="BeckAT , WardC , MendelsonM . An inventory for measuring depression. Archives of General Psychiatry1961;4:561-71.">Beck 1961</a>), and Hospital Anxiety and Depression Scale (Depression subscale, HADS‐D) (<a href="./references#CD003690-bbs2-0096" title="ZigmondAS , SnaithRP . The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandanavica1983;67(6):361-70.">Zigmond 1983</a>), or as measured on composite scales, such as the General Health Questionnaire (GHQ) (<a href="./references#CD003690-bbs2-0059" title="GoldbergDP . The Detection of Psychiatric Illness by Questionnaire. Vol. 21. Oxford: Oxford University Press, 1972.">Goldberg 1972</a>) </p> </li> <li> <p>Cognitive functioning: mean scores at end of treatment. Cognition as measured on scales such as the Mini‐Mental State Examination (MMSE) (<a href="./references#CD003690-bbs2-0056" title="FolsteinMF , FolsteinSE , McHughPR . 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research1975;12(3):189-98.">Folstein 1975</a>) </p> </li> <li> <p>Activities of daily living: mean scores at end of treatment. Activities of daily living as measured on scales such as the Barthel Index (BI) (<a href="./references#CD003690-bbs2-0073" title="MahoneyFI , BarthelDW . Functional evaluation: the Barthel Index. Maryland State Medical Journal1965;14:61-5.">Mahoney 1965</a>) </p> </li> <li> <p>Disadvantages of treatment were recorded as:</p> <ul id="CD003690-list-0007"> <li> <p>adverse events: death;</p> </li> <li> <p>adverse events: all; and</p> </li> <li> <p>adverse events: leaving the study early (including death).</p> </li> </ul> </li> <li> <p>We identified additional endpoints for use in further reviews, where measured.</p> <ul id="CD003690-list-0008"> <li> <p>Proportion who scored above accepted cut‐offs for identifying mood disorders, using mood‐rating scales. </p> </li> <li> <p>Proportion who met the standard psychiatric diagnostic criteria for major depression or dysthymia (Diagnostic and Statistical Manual of Mental Disorders (DSM): DSM‐IIIR, DSM‐IV) (<a href="./references#CD003690-bbs2-0046" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IIIR. Washington, DC: American Psychiatric Association, 1987.">APA 1987</a>; <a href="./references#CD003690-bbs2-0047" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association, 1994.">APA 1994</a>). </p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD003690-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>This review is an update of a previously published Cochrane Review (<a href="./references#CD003690-bbs2-0097" title="AllidaS , PatelK , HouseA , HackettML . Pharmaceutical interventions for emotionalism after stroke. Cochrane Database of Systematic Reviews2019, Issue 3. Art. No: CD003690. [DOI: 10.1002/14651858.CD003690.pub4]">Allida 2019</a>). The first version of this review was published in 2004 (<a href="./references#CD003690-bbs2-0100" title="HouseAO , HackettML , AndersonCS , HorrocksJA . Pharmaceutical interventions for emotionalism after stroke. Cochrane Database of Systematic Reviews2004, Issue 2. Art. No: CD003690. [DOI: 10.1002/14651858.CD003690]">House 2004</a>). For this update, we only searched the Specialised Register of Cochrane Stroke and the Cochrane Central Register of Controlled trials (CENTRAL) from 2008 until May 2022. </p> <section id="CD003690-sec-0024"> <h4 class="title">Electronic searches</h4> <p>Cochrane Stroke's Information Specialist searched the following databases:</p> <p> <ul id="CD003690-list-0009"> <li> <p>Cochrane Stroke Group Register;</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 7) in the Cochrane Library (searched 26 May 2022) (<a href="./appendices#CD003690-sec-0093">Appendix 1</a>); </p> </li> <li> <p>MEDLINE Ovid (1966 to 26 May 2022) (<a href="./appendices#CD003690-sec-0094">Appendix 2</a>); </p> </li> <li> <p>Embase Ovid (1980 to 26 May 2022) (<a href="./appendices#CD003690-sec-0096">Appendix 3</a>); </p> </li> <li> <p>CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature; 1982 to 26 May 2022) (<a href="./appendices#CD003690-sec-0098">Appendix 4</a>); </p> </li> <li> <p>PsycINFO Ovid (1967 to 26 May 2022) (<a href="./appendices#CD003690-sec-0100">Appendix 5</a>); </p> </li> <li> <p>BIOSIS Previews (Web of Science) (January 2002 to 26 May 2022) (<a href="./appendices#CD003690-sec-0102">Appendix 6</a>); and </p> </li> <li> <p>Science Citation Index Expanded (SCI‐EXPANDED), Social Sciences Citation Index (SSCI), and Arts &amp; Humanities Citation Index (A&amp;HCI) within Web of Science (January 2002 to 26 May 2022) (<a href="./appendices#CD003690-sec-0104">Appendix 7</a>). </p> </li> </ul> </p> <p>We also searched the following resources using "emotion" or "laughing" or "tearful" or "pseudobulbar affect" and "stroke" or "cerebral hemorrhage" or "brain ischemia" from inception. </p> <p> <ul id="CD003690-list-0010"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 26 May 2022); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="https://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>; searched 26 May 2022); and </p> </li> <li> <p>ProQuest Dissertations &amp; Theses Global database (<a href="https://www.proquest.com" target="_blank">www.proquest.com</a>; searched 26 May 2022). </p> </li> </ul> </p> <p>The full search strategies for other resources are in <a href="./appendices#CD003690-sec-0106">Appendix 8</a>. </p> </section> <section id="CD003690-sec-0025"> <h4 class="title">Searching other resources</h4> <section id="CD003690-sec-0026"> <h5 class="title">Personal communication</h5> <p>We contacted the study authors for information on ongoing trials or to request additional study data. </p> </section> <section id="CD003690-sec-0027"> <h5 class="title">Reference lists</h5> <p>We searched the reference lists of relevant trials and systematic reviews and reviewed chapters in books on the prevention and treatment of depression and management of stroke, including but not limited to, reviews of the management of stroke, books specifically directed at the treatment or prevention of depression, and those on stroke and old age. </p> </section> </section> </section> <section id="CD003690-sec-0028"> <h3 class="title" id="CD003690-sec-0028">Data collection and analysis</h3> <section id="CD003690-sec-0029"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SA, MH) discarded irrelevant citations based on the title of the publication and its abstract. If we thought that an article could possibly be relevant, we retrieved the full‐length article for further assessment. Two review authors (SA, MH) independently selected the trials for inclusion in the review from the culled citation list. We obtained translations of potentially relevant non‐English language articles. We resolved disagreements by discussion, and one review author (AH) confirmed the final list and adjudicated any persisting differences. We present the selection process in a PRISMA flow diagram (<a href="./references#CD003690-bbs2-0081" title="PageMJ , McKenzieJE , BossuytPM , BoutronI , HoffmannTC , MulrowCD , et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021;372:n71.">Page 2021</a>). We listed the included trials under <a href="./references#CD003690-sec-0117" title="">Characteristics of included studies</a>, and we listed the trials that we ultimately excluded under <a href="./references#CD003690-sec-0118" title="">Characteristics of excluded studies</a> and provided the primary reasons for exclusion. </p> </section> <section id="CD003690-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (SA, MH) independently extracted study characteristics and outcome data from included trials on specially designed forms. We cross‐checked and entered the data into Review Manager 5 (<a href="./references#CD003690-bbs2-0084" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager</a>). We obtained missing information from the study authors when possible. We resolved disagreements by discussion or through consultation with a third review author (AH). If outcome data were not reported in a usable way, we reported this in the notes in the <a href="./references#CD003690-sec-0117" title="">Characteristics of included studies</a> table. </p> <p>We collected data on the following:</p> <p> <ul id="CD003690-list-0011"> <li> <p>the report: author, year, and source of publication;</p> </li> <li> <p>the study: sample characteristics, social demography, definition and criteria used for emotionalism; </p> </li> <li> <p>the participants: stroke sequence (first‐ever versus recurrent), social situation, time since stroke onset, history of psychiatric illness, current neurological status, current treatment for depression, coronary artery disease; </p> </li> <li> <p>the research design and features: sampling mechanism, treatment assignment mechanism, adherence rates, non‐response rates, length of follow‐up; </p> </li> <li> <p>the intervention: type, duration, dose, timing, mode of delivery; and</p> </li> <li> <p>the effect size: sample size, nature of outcome, estimate, and standard error.</p> </li> </ul> </p> <p>To allow an intention‐to‐treat analysis, we sought data irrespective of adherence, whether the participants were subsequently deemed ineligible or otherwise excluded from treatment or follow‐up. </p> <p>We checked all of the extracted data for agreement between review authors. To avoid introducing bias, we requested this unpublished information in writing then entered it into Review Manager 5 (<a href="./references#CD003690-bbs2-0084" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager</a>). </p> </section> <section id="CD003690-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SA, MH) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003690-bbs2-0064" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). We resolved any disagreements by discussion or by involving another author (AH). We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD003690-list-0012"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>In accordance with RoB 1, we graded potential sources of bias as high, low, or unclear and provided a quote from the study report together with justification for our judgement in the risk of bias table. We summarised the risk of bias judgements across different trials for each of the domains listed. </p> <p>When considering treatment effects, we took into account the risk of bias for the trials that contributed to that outcome. </p> </section> <section id="CD003690-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <section id="CD003690-sec-0033"> <h5 class="title">Dichotomous data</h5> <p>The primary outcomes of interest were the proportion of participants with improved emotionalism scores (reduced symptoms) at the end of follow‐up on the CNS‐LS (<a href="./references#CD003690-bbs2-0077" title="MooreS , GreshamL , BrombergM , KasarkisE , SmithR . A self-report measure of emotional lability. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):89-93.">Moore 1997</a>), TEARS‐Q (<a href="./references#CD003690-bbs2-0052" title="BroomfieldNM , WestR , HouseA , MunyombweT , BarberM , GraceyF , et al. Psychometric evaluation of a newly developed measure of emotionalism after stroke (TEARS-Q). Clinical Rehabilitation2021;35(6):894-903.">Broomfield 2021</a>), and CIBIC (<a href="./references#CD003690-bbs2-0070" title="KnopmanD , KnappMJ , GraconSI , DavisCS . The Clinician Based Impression (CIBI): a clinician’s global change rating scale in Alzheimer’s disease. Neurology1994;44:2315–21.">Knopman 1994</a>), and diminished tearfulness, and the proportion who showed a 50% reduction in abnormal emotional behaviour (crying or laughing) at the end of treatment. For all dichotomous outcomes, we calculated Mantel‐Haenszel risk ratios (RRs) with 95% confidence intervals (CIs) where appropriate, using random‐effects analyses. </p> </section> <section id="CD003690-sec-0034"> <h5 class="title">Continuous data</h5> <p>For continuous outcomes, if ordinal scale data appeared to be approximately normally distributed or if the analysis suggested parametric tests were appropriate, we treated the outcome measures as continuous. If there were at least two trials that reported the same outcomes, then we calculated a mean difference (MD) across the trials. Where different outcome measures were used, we planned to calculate a standardised mean difference (SMD). </p> </section> </section> <section id="CD003690-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>No unit of analysis issues were anticipated in the trials we included.</p> </section> <section id="CD003690-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>We wrote to the authors of all included trials requesting data that were unavailable or ambiguous in the published articles. Three authors responded with the requested additional data (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>). Another study author responded stating that the requested additional data were unavailable (<a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>). We did not receive responses from the remaining study authors. </p> </section> <section id="CD003690-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological heterogeneity by examining the study characteristics of trials. We used the I<sup>2</sup> statistic to measure heterogeneity amongst the trials in each analysis (<a href="./references#CD003690-bbs2-0054" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). We interpreted the heterogeneity of each analysis based on the following cut‐offs: </p> <p> <ul id="CD003690-list-0013"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity; and</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>If there was definite evidence of heterogeneity (I<sup>2</sup> statistic &gt; 50%), we explored the potential reasons for the differences by performing subgroup analyses. We reported similarities between interventions, participants, design, and outcomes in the <a href="#CD003690-sec-0046">Included studies</a> subsection. </p> </section> <section id="CD003690-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not assess publication bias as fewer than 10 trials were available. We attempted to avoid language bias by including trials irrespective of language of publication. </p> </section> <section id="CD003690-sec-0039"> <h4 class="title">Data synthesis</h4> <p>We analysed data using Review Manager 5 and pooled data for meta‐analysis when trials assessed similar treatment and had similar outcomes (<a href="./references#CD003690-bbs2-0084" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager</a>). We conducted a meta‐analysis using available or calculated SMDs for continuous outcomes, and risk ratios (RRs) for dichotomous outcomes. We included in the results measures of uncertainty, such as 95% CIs and estimates of the I<sup>2</sup> statistic. </p> </section> <section id="CD003690-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If there were at least two trials that reported the same outcomes, we reviewed the data for appropriateness of pooling. If the heterogeneity remained high, we combined the trials using random‐effects analyses with cautious interpretation, or did not combine them at all. </p> </section> <section id="CD003690-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We explored the sensitivity of the combined estimate to individual trials by leaving one study out due to high risk of bias and methodological differences. We then calculated the combined effect of the remaining trials and compared the results with the combined effect based on all the trials. </p> </section> <section id="CD003690-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a summary of findings table using the primary outcome emotionalism, measured as the proportion of participants achieving at least a 50% reduction in abnormal emotional behaviour at the end of treatment, improved score on the CNS‐LS, improved CIBIC, and diminished tearfulness. Other outcomes included depression, cognitive functioning, activities of daily living, and adverse events. </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence as it relates to the trials that contributed data to the meta‐analyses for the prespecified outcomes. We used the methods and recommendations described in Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003690-bbs2-0089" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Schünemann 2019</a>), and we created the tables using GRADEpro GDT software (<a href="./references#CD003690-bbs2-0061" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 28 April 2022. Available at gradepro.org.">GRADEpro GDT</a>). </p> <p>By treating all pharmaceutical interventions as one comparator, we pooled the data from the trials comparing pharmaceutical interventions to placebo into a single meta‐analysis and reported these in <a href="./full#CD003690-tbl-0001">summary of findings Table 1</a>. We documented in the footnotes of the tables all decisions to downgrade the certainty of trials, and we made comments to aid the reader's understanding of the review where necessary. </p> <p>An experienced review author (SA) made judgements about the certainty of the evidence; another author (MLH) independently checked these judgements, and a third author (AH) resolved any disagreements. We justified, documented, and incorporated these judgements into our reporting of results for each outcome. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003690-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003690-sec-0043"></div> <section id="CD003690-sec-0044"> <h3 class="title">Description of studies</h3> <section id="CD003690-sec-0045"> <h4 class="title">Results of the search</h4> <p>In total, we identified 6754 records; of these, we retrieved 6202 records through database searching. We found 541 additional references by searching other resources. After removing 1332 duplicates, we screened 5422 titles and abstracts and excluded 5377 irrelevant records. We retrieved full‐text reports for the remaining 45 trials. After reading the full texts, we excluded 35 trials as they did not meet the review eligibility criteria (see <a href="#CD003690-fig-0001">Figure 1</a>). We have provided primary reasons for exclusion in the <a href="./references#CD003690-sec-0118" title="">Characteristics of excluded studies</a> tables and in <a href="#CD003690-fig-0001">Figure 1</a>. Although one trial met the inclusion criteria, baseline evaluation of the trial occurred at one month post‐treatment (<a href="./references#CD003690-bbs2-0024" title="KimJS , LeeEJ , ChangDI , ParkJH , AhnSH , ChaJK , et al. The efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry2017;4(1):33-41. NCT01278498. The preventive effect of escitalopram on depression and related emotional disorders in acute stroke patients. clinicaltrials.gov/ct2/show/NCT01278498 (first received 19 January 2011). ">Kim 2017b</a>); we considered this trial a 'dropout' (<a href="#CD003690-tbl-0002">Table 1</a>). </p> <div class="figure" id="CD003690-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD003690-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>In the previous published version of this review (<a href="./references#CD003690-bbs2-0098" title="HackettML , YangM , AndersonCS , HorrocksJA , HouseA . Pharmaceutical interventions for emotionalism after stroke. Cochrane Database of Systematic Reviews2010, Issue 2. Art. No: CD003690. [DOI: 10.1002/14651858.CD003690.pub3]">Hackett 2010</a>), we identified two trials that met the inclusion criteria (<a href="./references#CD003690-bbs2-0008" title="AizawaT , KaseM , KutsuzawaT , HasegawaT , SekimotoH , OmaeT . Clinical evaluation on the effect of cyclandelate in the treatment of cerebrovascular diseases: double-blind comparative placebo-controlled clinical study with cinnarizine as a basic treatment. Rinsho Hyoka1977;5(3):659-86. ">Aizawa 1977</a>; <a href="./references#CD003690-bbs2-0033" title="OhtomoE , KutsuzawaT , ArakiG , HiraiS , TerashiA , KuzuyaF , et al. Clinical usefulness of tiapride on psychiatric symptoms caused by cerebrovascular disorders: a multi-center double-blind study in comparison with inactive placebo. Rinsho Hyoka1985;13(2):295-332. ">Ohtomo 1985</a>). However, both trials included participants with cerebral arteriosclerosis, and neither presented outcome data by those diagnosed with emotionalism at entry. We considered these two trials as 'dropouts'. See <a href="#CD003690-tbl-0002">Table 1</a> for more detailed information on these trials. </p> </section> <section id="CD003690-sec-0046"> <h4 class="title">Included studies</h4> <p>From the previous update of this review, there were a total of seven included trials with 239 participants. Two trials had a cross‐over design (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>), and outcome data were not available from the first phase (precross‐over) in an appropriate format for inclusion as a parallel randomised controlled trial (RCT). Therefore, this review primarily reports data from five trials with a total of 213 participants (see <a href="./references#CD003690-sec-0117" title="">Characteristics of included studies</a>). Of these, we had included five trials in the first version of this review in 2004 (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>), and we added two trials to the previous update in 2010 (<a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>). For this present review, we found no new trials. </p> <section id="CD003690-sec-0047"> <h5 class="title">Participants</h5> <p>All trials in this review included men and women. The mean or median age of participants ranged from 57.8 to 73 years. Five trials reported the time between stroke and randomisation into the trial, with recruitment occurring in and out of hospital and the range covering three days to 13 years (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>). </p> </section> <section id="CD003690-sec-0048"> <h5 class="title">Interventions</h5> <p>Five trials assessed the efficacy of selective serotonin reuptake inhibitors (SSRIs): citalopram (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>), fluoxetine (<a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>), and sertraline (<a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>); two assessed tricyclic antidepressants: amitriptyline (<a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>), and nortriptyline (<a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>). Duration of treatment ranged from 10 to 182 days. </p> </section> <section id="CD003690-sec-0049"> <h5 class="title">Comparator intervention(s)</h5> <p>Only one trial did not compare the active intervention with a placebo‐matched control, but instead combined the active treatment with a 'stomach medicine' to disguise taste and smell, with the control group receiving the stomach medicine only (<a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>). </p> </section> <section id="CD003690-sec-0050"> <h5 class="title">Outcomes</h5> <section id="CD003690-sec-0051"> <h6 class="title">Primary outcome: emotionalism</h6> <p>No standard criteria were used to define emotionalism at entry across the trials. Emotionalism was measured in seven different ways in the seven trials (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>), and no more than two trials used the same method of assessment. <a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a> and <a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a> assessed emotionalism using a semi‐structured interview modified from Lawson and Macleod (<a href="./references#CD003690-bbs2-0072" title='LawsonJR , MacleodRD . The use of imipramine ("Tofranil") and other psychotropic drugs in organic emotionalism. British Journal of Psychiatry1969;115:281-5.'>Lawson 1969</a>). In <a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>, the presence or absence of emotionalism was assessed using seven questions based on the trial by House and colleagues (<a href="./references#CD003690-bbs2-0065" title="HouseA , DennisM , MolyneuxA , WarlowC , HawtonK . Emotionalism after stroke. BMJ1989;298(6679):991-4.">House 1989</a>). Other trials confirmed the presence of emotionalism through clinical diagnosis made by a psychiatrist (<a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>), or asking the participants and their relatives whether increased tearfulness or inappropriate laughing has occurred at any time (<a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>), or on more than two occasions (<a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>). </p> </section> <section id="CD003690-sec-0052"> <h6 class="title">Secondary outcomes</h6> <p>A variety of additional outcomes were assessed in each trial. Several trials assessed, but did not report, outcome data for depression (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>), activities of daily living (<a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>), and cognitive functioning (<a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>). Only three trials reported that they systematically measured and reported adverse events (<a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>). </p> </section> </section> <section id="CD003690-sec-0053"> <h5 class="title">Funding sources</h5> <p>Pharmaceutical companies provided the antidepressant and placebo in four trials (Lundbeck (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>), Pfizer (<a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>), and Sandoz (<a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>)) and additional funding, including statistical advice, for <a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>. Funding from the Ministry of Health supported a further trial (<a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>), and the source of funding was unclear for two trials (<a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>). </p> </section> </section> <section id="CD003690-sec-0054"> <h4 class="title">Excluded studies</h4> <p>We have listed the 35 excluded trials and the reasons for their exclusion in the <a href="./references#CD003690-sec-0118" title="">Characteristics of excluded studies</a> tables. The main reasons for exclusion were no placebo used (<a href="./references#CD003690-bbs2-0010" title="AtarashiJ , OhtomoE , KogureK , HiraiS , TazakiY , ArakiG , et al. Clinical utility of HYG-FAS in treatment of cerebrovascular disorders: multi-center double-blind study in comparison with hydergine tablet 2mg. Rinsho Hyoka1988;16(3):425-86. ">Atarashi 1988</a>; <a href="./references#CD003690-bbs2-0011" title="BassiS , AlbizzatiMG , SbacchiM , FrattolaL . Chronic cerebrovascular disorders: clinical study with cyclandelate. British Journal of Clinical Practice1984;38:344-9. ">Bassi 1984</a>; <a href="./references#CD003690-bbs2-0029" title="MullerU , MuraiT , Bauer-WittmundT , CramonDY . Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Injury1999;13(10):805-11. ">Muller 1999</a>), participants had not experienced stroke or the number with stroke was unclear (<a href="./references#CD003690-bbs2-0008" title="AizawaT , KaseM , KutsuzawaT , HasegawaT , SekimotoH , OmaeT . Clinical evaluation on the effect of cyclandelate in the treatment of cerebrovascular diseases: double-blind comparative placebo-controlled clinical study with cinnarizine as a basic treatment. Rinsho Hyoka1977;5(3):659-86. ">Aizawa 1977</a>; <a href="./references#CD003690-bbs2-0033" title="OhtomoE , KutsuzawaT , ArakiG , HiraiS , TerashiA , KuzuyaF , et al. Clinical usefulness of tiapride on psychiatric symptoms caused by cerebrovascular disorders: a multi-center double-blind study in comparison with inactive placebo. Rinsho Hyoka1985;13(2):295-332. ">Ohtomo 1985</a>; <a href="./references#CD003690-bbs2-0037" title="SchifferRB , HerndonRM , RudickRA . Treatment of pathologic laughing and weeping with amitriptyline. New England Journal of Medicine1985;312(23):1480-2. ">Schiffer 1985</a>; <a href="./references#CD003690-bbs2-0039" title="SeligerGM , HornsteinA , FlaxJ , HerbertJ , SchroederK . Fluoxetine improves emotional incontinence. Brain Injury1992;6(3):267-70. ">Seliger 1992</a>; <a href="./references#CD003690-bbs2-0040" title="UdakaF , YamaoS , NagataH , NakamuraS , KameyamaM . Pathologic laughing and crying treated with levodopa. Archives of Neurology1984;41(10):1095-6. ">Udaka 1984</a>), participants had emotionalism and dementia or Alzheimer's (<a href="./references#CD003690-bbs2-0016" title="DoodyRS , D'AmicoS , CutlerAJ , ShinP , LedonF , YonanC , et al. Safety, tolerability and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with Alzheimer's Disease/Dementia: PRISM-II. Annals of Neurology2014;76(Suppl 18):S99-S100. ">Doody 2014</a>; <a href="./references#CD003690-bbs2-0036" title="SauveW , AlexanderDN , CutlerAJ , D'AmicoS , HammondFM , ZorowitzRD , et al. Neurological and psychiatric comorbidities assessment in the PRISM II study of dextromethorphan/quinidine for treatment of pseudobulbar affect. CNS Spectrums2017;22(1):104. ">Sauve 2017</a>), not a RCT (<a href="./references#CD003690-bbs2-0009" title="AllenC , ZarowitzB , O'SheaT , PetersonE , YonanC , WatermanF . Identification of pseudobulbar affect symptoms in the nursing home setting: development and assessment of a screening tool. Geriatric Nursing2018;39(1):54-9. ">Allen 2018</a>; <a href="./references#CD003690-bbs2-0012" title="ChenYR , HuangYP , LinSJ , KuanTH , LinCH . Effectiveness of quetiapine for poststroke pathological laughing: case report and review of literature. Clinical Neuropharmacology2010;33(6):319-22. ">Chen 2010</a>; <a href="./references#CD003690-bbs2-0014" title="ColamonicoJ , FormellaA , BradleyW . Psuedobulbar affect: burden of illness in the USA. Advances in Therapy2012;29(9):775-98. ">Colamonico 2012</a>; <a href="./references#CD003690-bbs2-0023" title="KimJS . Management of post-stroke mood and emotional disturbances. Expert Review of Neurotherapeutics2017;17(12):1179-88. ">Kim 2017a</a>; <a href="./references#CD003690-bbs2-0027" title="ManzoJF , Health RL, BlonderLX . The interpersonal management of crying among survivors of stroke. Sociological Spectrum1998;18(2):161-84. ">Manzo 1998</a>; <a href="./references#CD003690-bbs2-0032" title="NCT01799941. Safety, tolerability and effectiveness of nuedexta in the treatment of pseudobulbar affect (PBA). clinicaltrials.gov/ct2/show/NCT01799941 (first received 27 February 2013). ">NCT01799941 2013</a>; <a href="./references#CD003690-bbs2-0038" title="SchoedelKA , MorrowSA , SellersEM . Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Neuropsychiatric Disease and Treatment2014;10:1161-74. ">Schoedel 2014</a>; <a href="./references#CD003690-bbs2-0041" title="WorkSS , ColamonicoJA , BradleyWG , KayeRE . Pseudobulbar affect: an under-recognized and under-treated neurological disorder. Advances in Therapy2011;28(7):586-601. ">Work 2011</a>; <a href="./references#CD003690-bbs2-0042" title="YangLPH , DeeksED . Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect. Drugs2015;75(1):83-90. ">Yang 2015</a>), open‐label trial (<a href="./references#CD003690-bbs2-0015" title="D'AmicoS , AlexanderDN , CutlerAJ , ZorowitzRD , DavisCS , ShinP , et al. Safety and tolerability of dextromethorphan/quinidine in older patients. American Journal of Geriatric Psychiatry2017;25(3 Suppl 1):S142. ">D'Amico 2017</a>; <a href="./references#CD003690-bbs2-0021" title="FormellaAE , AlexanderDN , CutlerAJ , D'AmicoS , HammondFM , SauveW , et al. Dextromethorpha/quinidine improved symptoms of pseudobulbar affect irrespective of concomitant antidepressant use. CNS Spectrums2017;22(1):64-5. ">Formella 2017a</a>; <a href="./references#CD003690-bbs2-0022" title="FormellaAE , AlexanderDN , CutlerAJ , D'AmicoS , HammondFM , SauveW , et al. Dextromethorphan/quinidine improved symptoms of pseudobulbar affect irrespective of concomitant antidepressant use. Neurology2017;88 Suppl 1:1-2. ">Formella 2017b</a>), emotionalism was not investigated either at baseline (<a href="./references#CD003690-bbs2-0017" title="EUCTR2004-004803-39-DE. SAINT II (Stroke - Acute Ischemic - NXY Treatment) A double blind, randomized, placebo controlled, parallel group, multicenter, phase IIb/III study to assess the efficacy and safety of intravenous NXY-059 in acute ischemic stroke - SAINT-II. www.clinicaltrialsregister.eu/ctr-search/trial/2004-004803-39/results (first received 18 August 2005). ">EUCTR2004‐004803‐39‐DE 2006</a>; <a href="./references#CD003690-bbs2-0018" title="EUCTR2011-005541-12-DK. Efficacy of escitalopram treatment in acute stroke and the role of specific genotypes in stroke. www.clinicaltrialsregister.eu/ctr-search/trial/2011-005541-12/DK (first received 27 February 2012). ">EUCTR2011‐005541‐12‐DK 2012</a>; <a href="./references#CD003690-bbs2-0019" title="EUCTR2011-006130-16-SE. Establishing the effect(s) and safety of fluoxetine in non-depressed stroke patients initiated in the acute phase of stroke. www.clinicaltrialsregister.eu/ctr-search/trial/2011-006130-16/SE (first received 16 June 2014). ">EUCTR2011‐006130‐16‐SE 2014</a>; <a href="./references#CD003690-bbs2-0020" title="EUCTR2013-002253-30-DK. Efficacy of citalopram treatment in acute stroke [Clinical Trials Register]. www.www.clinicaltrialsregister.eu/ctr-search/trial/2013-002253-30/DK (first received 9 September 2013). ">EUCTR2013‐002253‐30‐DK 2013</a>; <a href="./references#CD003690-bbs2-0024" title="KimJS , LeeEJ , ChangDI , ParkJH , AhnSH , ChaJK , et al. The efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry2017;4(1):33-41. NCT01278498. The preventive effect of escitalopram on depression and related emotional disorders in acute stroke patients. clinicaltrials.gov/ct2/show/NCT01278498 (first received 19 January 2011). ">Kim 2017b</a>; <a href="./references#CD003690-bbs2-0026" title="LorwatanapongsaS , ChompoonuchS , PongpakdeeS , MayotarnS , PiyatanontK , AwaiwanontA . Randomized controlled trial of fluoxetine or placebo on quality of life after acute ischemic stroke (RTAF-QoL). In: 36th Annual Meeting, The Royal College of Physicians of Thailand. 2020. ">Lorwatanapongsa 2020</a>; <a href="./references#CD003690-bbs2-0035" title="RasmussenA , KlysnerR , MellerupE . A double-blind, placebo-controlled study of the prophylactic effect of sertraline in post stroke emotional lability. Conference poster2000. RasmussenA , LundeM , PoulsenDL , SorensenK , QvitzauS , BechP . A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics2003;44(3):216-21. RasmussenA . A double blind controlled study of the influence of sertraline on the incidence of post stroke depression and on emotional lability [PhD Thesis]. Copenhagen (Denmark): University of Copenhagen, 2000. RasmussenA . Depression and stroke. Nordic Journal of Psychiatry2001;55(4):288. RasmussenA . Post-stroke emotional lability. A double-blind psychopharmacological treatment with sertralin. Nordic Journal of Psychiatry2000;54:35. ">Rasmussen 2000</a>) or at end of treatment (<a href="./references#CD003690-bbs2-0028" title="MollerM , AndersenG , GjeddeA . Serotonin 5HT1A receptor availability and pathological crying after stroke. Acta Neurologica Scandinavica2007;116(2):83-90. ">Moller 2007</a>; <a href="./references#CD003690-bbs2-0030" title="NarushimaP , KosierJ , RobinsonR . Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up. Journal of Nervous and Mental Disease2002;190(5):296-303. ">Narushima 2002</a>; <a href="./references#CD003690-bbs2-0034" title="OtomoE , SasoS , ArakiG , HiraiS , AtarashiJ , HasegawaK , et al. Clinical evaluation of amantadine hydrochloride (Symmetrel) in the treatment of cerebrovascular disorders with psychiatric symptoms: multi-center double-blind study in comparison with placebo. Rinsho Hyoka1984;12(2):321-67. ">Otomo 1984</a>), baseline evaluation of emotionalism occurred at one month post‐treatment (<a href="./references#CD003690-bbs2-0024" title="KimJS , LeeEJ , ChangDI , ParkJH , AhnSH , ChaJK , et al. The efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry2017;4(1):33-41. NCT01278498. The preventive effect of escitalopram on depression and related emotional disorders in acute stroke patients. clinicaltrials.gov/ct2/show/NCT01278498 (first received 19 January 2011). ">Kim 2017b</a>), method of randomisation was ineffectual (<a href="./references#CD003690-bbs2-0025" title='LawsonIR , MacLeodRD . The use of imipramine ("Tofranil") and other psychotropic drugs in organic emotionalism. British Journal of Psychiatry1969;115(520):281-5. '>Lawson 1969</a>), and the trial assessed prevention rather than treatment of emotionalism (<a href="./references#CD003690-bbs2-0031" title="NCT01278498. The preventive effect of escitalopram on depression and related emotional disorders in acute stroke patients. clinicaltrials.gov/ct2/history/NCT01278498 (first received 18 January 2011). ">NCT01278498 2011</a>). </p> </section> <section id="CD003690-sec-0055"> <h4 class="title">Ongoing studies</h4> <p>We identified no ongoing trials.</p> </section> <section id="CD003690-sec-0056"> <h4 class="title">Studies awaiting classification</h4> <p>We identified no trials awaiting classification.</p> </section> <section id="CD003690-sec-0057"> <h4 class="title">New studies found for inclusion in this update</h4> <p>We identified no new trials in this update.</p> </section> </section> <section id="CD003690-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>In <a href="#CD003690-fig-0002">Figure 2</a>, we present a graphical summary of the risk of bias assessments we performed for the seven included trials (based on the seven risk of bias domains). <a href="#CD003690-fig-0003">Figure 3</a> provides a summary of risk of bias for each included trial. We have provided the reasons for judgements in the risk of bias tables. For clarification, we have provided quotes in these tables. </p> <div class="figure" id="CD003690-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003690-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003690-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003690-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003690-sec-0059"> <h4 class="title">Allocation</h4> <p>We rated three trials as having a low risk of selection bias and four as having an unclear risk. Two of the trials did not report the method used for sequence generation (<a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>). One trial randomised participants using a random number allocation list (<a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>), and three trials randomised participants using a computer‐generated number sequence (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>). One trial administered the intervention after random number assignment (<a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>). Four trials clearly reported allocation concealment (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>). </p> </section> <section id="CD003690-sec-0060"> <h4 class="title">Blinding</h4> <p>We assessed four trials as having a low risk of performance and detection bias (<a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>). Although three trials reported that they were double‐blind, they failed to report exactly who was blinded (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>). </p> </section> <section id="CD003690-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>We judged six of the trials as having a low risk of bias for outcome reporting (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>). One trial was at high risk, as the total number of participants stated was inconsistent. We rated trials as having a high risk of bias if dropout rates were uneven between groups and the reason for dropout was suspected to be related to group allocation. We also rated trials as high risk if investigators did not report how dropout was dealt with (e.g. intention‐to‐treat analysis and last observation carried forward). </p> </section> <section id="CD003690-sec-0062"> <h4 class="title">Selective reporting</h4> <p>We rated risk of bias from selective reporting as low risk for all the trials (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>). </p> </section> <section id="CD003690-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>We judged the risk of other potential sources of bias as unclear for all the trials as trial authors either did not report the source of funding or the reported funding source was a pharmaceutical company with no associated statement indicating their involvement in trial conduct or analysis. </p> </section> </section> <section id="CD003690-sec-0064"> <h3 class="title" id="CD003690-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD003690-tbl-0001"><b>Summary of findings 1</b> Pharmaceutical interventions compared to placebo for emotionalism after stroke</a> </p> <p>For details of the comparisons made for trials with outcome data, please refer to the <a href="./references#CD003690-sec-0091" title="">Data and analyses</a> section. Labelling of the x‐axis on the forest plots changes because of variation in the method of measurement and direction of the outcome scale. </p> <section id="CD003690-sec-0065"> <h4 class="title">Primary outcome</h4> <section id="CD003690-sec-0066"> <h5 class="title">Emotionalism</h5> <p>It is uncertain whether antidepressants (fluoxetine) increase the number of people who have a 50% reduction in emotionalism when compared to placebo (risk ratio (RR) 0.26, 95% confidence interval (CI) 0.09 to 0.77; P = 0.02; 1 randomised controlled trial (RCT), 19 participants) because the certainty of the evidence is very low (<a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-fig-0004" title="">Analysis 1.1</a>, subgroup 1.1.1). We observed an improvement (reduction) in tearfulness when compared to placebo (RR 0.32, 95% CI 0.12 to 0.86; P = 0.02; 3 RCTs, 164 participants; moderate‐certainty evidence; <a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>; <a href="./references#CD003690-fig-0004" title="">Analysis 1.1</a>, subgroup 1.1.4). </p> <p>Sertraline may have little to no effect on the Center for Neurologic Study ‐ Lability Scale (CNS‐LS) and Clinician Interview‐Based Impression of Change (CIBIC) scores compared to placebo (RR 0.20, 95% CI 0.03 to 1.50; P = 0.12; 1 RCT, 28 participants) because the certainty of the evidence is low (<a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-fig-0004" title="">Analysis 1.1</a>). The point estimates were consistent with large treatment effects for all five trials; however, the CIs were wide for three trials (<a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>), so it is possible that the treatment may have had only a small beneficial effect, or in the case of one trial (<a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>), the treatment may even have had a small harmful effect on two endpoints (see subgroups 1.1.2 and 1.1.4). </p> </section> </section> <section id="CD003690-sec-0067"> <h4 class="title">Secondary outcomes</h4> <section id="CD003690-sec-0068"> <h5 class="title">Emotionalism scores</h5> <p>It is uncertain whether nortriptyline lowers scores (fewer emotionalism symptoms) on the Pathological Laughter and Crying Scale (PLCS) when compared with placebo (mean difference (MD) ‐8.40, 95% CI ‐11.56 to ‐5.24; P &lt; 0.00001; 1 RCT, 28 participants) because the certainty of the evidence is low (<a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>; <a href="./references#CD003690-fig-0005" title="">Analysis 1.2</a>, subgroup 1.2.1). </p> </section> <section id="CD003690-sec-0069"> <h5 class="title">Depression</h5> <p>The moderate reduction in depression that was observed between treatment groups at the end of one trial (<a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>; <a href="./references#CD003690-fig-0006" title="">Analysis 1.3</a>, subgroup 1.3.1) has been mediated by the addition of a second trial (<a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>), and is not apparent after controlling for differences in depression between groups at baseline (standardised mean difference (SMD) 0.82, 95% CI 2.14 to 0.51; P = 0.01; 2 RCTs, 72 participants; very low‐certainty evidence) (see <a href="./references#CD003690-fig-0007" title="">Analysis 1.4</a>, subgroup 1.4.1, where the CI includes 0 and the possibility of a negative treatment effect). </p> </section> <section id="CD003690-sec-0070"> <h5 class="title">Cognitive functioning</h5> <p>One trial provided data concerning this outcome; nortriptyline had no effect on cognitive functioning when compared with placebo (MD 0.30, 95% CI ‐3.27 to 2.67; P = 0.84; 1 RCT, 28 participants; low‐certainty evidence; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>; <a href="./references#CD003690-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD003690-sec-0071"> <h5 class="title">Activities of daily living</h5> <p>One trial addressed activities of daily living and found no treatment effect on activities of daily living (MD 1.40, 95% CI ‐5.22 to 2.42; P = 0.47; 1 RCT, 28 participants; low‐certainty evidence; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>; <a href="./references#CD003690-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD003690-sec-0072"> <h5 class="title">Disadvantages of treatment</h5> <p>Two trials systematically recorded and reported adverse events (<a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>). Other trials provided selected data on some adverse events (<a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>), or those leaving the trial early (<a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>). </p> <section id="CD003690-sec-0073"> <h6 class="title">Death</h6> <p>We saw no differences between groups with the six trials reporting deaths (RR 0.59, 95% CI 0.08 to 4.50; P = 0.61; 6 RCTs, 172 participants; moderate‐certainty evidence; <a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>; <a href="./references#CD003690-fig-0010" title="">Analysis 1.7</a>). Deaths occurred in two trials: one in each group (<a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>), and one death only in the placebo group (<a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>). </p> </section> <section id="CD003690-sec-0074"> <h6 class="title">All adverse events</h6> <p>We saw no difference in central nervous system events, gastrointestinal effects, or other adverse events between groups. Confidence intervals were extremely wide and all included unity (see <a href="./references#CD003690-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD003690-sec-0075"> <h6 class="title">Leaving the trial early</h6> <p>Two trials showed that participants who were allocated active treatment were less likely to leave the trials early (<a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>); three other trials showed that participants who were allocated active treatment were more likely to leave the trials early, giving a pooled estimate of no effect. However, CIs were extremely wide (<a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>), and all included unity (see <a href="./references#CD003690-fig-0012" title="">Analysis 1.9</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003690-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003690-sec-0076"></div> <section id="CD003690-sec-0077"> <h3 class="title" id="CD003690-sec-0077">Summary of main results</h3> <p>This review provides very low‐ to moderate‐certainty evidence that antidepressants may reduce the frequency and severity of crying episodes. No harms and no trials of other pharmaceutical interventions were identified. We have downgraded the certainty of the evidence due to several methodological deficiencies. These deficiencies include the type of participants included, the definition and diagnosis of emotionalism used, the inclusion of some comorbidities, the small number of trials and participants contributing to most endpoints, and the generally poor trial design and reporting of results. </p> <p>In summary, these trials appear to add little to case reports and case series. They provide suggestive, but not definitive, evidence that antidepressants can reduce the frequency of crying (sometimes abolishing it altogether). The effect does not seem specific to one drug or class of drugs. </p> </section> <section id="CD003690-sec-0078"> <h3 class="title" id="CD003690-sec-0078">Overall completeness and applicability of evidence</h3> <p>The present review included seven trials with a total of 239 participants (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>). Two trials had a cross‐over design (<a href="./references#CD003690-bbs2-0001" title="AndersenG , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Journal of Neurology1994;241 Suppl 1:S81. AndersenG , VestergaardK , RiisJO . Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences1993;20 Suppl 4:S115. AndersenG , VestergaardK , RiisJO . Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica1994;89:151. FlickerC , AndersonG . Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society1998;46(9):S67. ">Andersen 1993</a>; <a href="./references#CD003690-bbs2-0006" title="OhkawaS , MoriE , YamadoriA . Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku1989;29(9):1183-5. ">Ohkawa 1989</a>), and outcome data were not available from the first phase (precross‐over) in an appropriate format for inclusion as a parallel randomised controlled trial (RCT). Thus, the results of the review were based on five trials with a total of 213 participants. Overall, there were no standard criteria for defining emotionalism at entry and no standard measures of emotionalism across all of the included trials. We considered three trials as 'dropouts' as outcome data were not available in the format appropriate for a parallel RCT and baseline was completed post‐treatment. As a result, there were a small number of trials and participants contributing to most endpoints. The accuracy of the findings of this systematic review and meta‐analysis is based on the studies that met the eligibility criteria. We will incorporate new data in future updates. </p> <p>In general, clinical trials are carried out on selected groups of individuals, while the usefulness of the information derived lies primarily in the ability to generalise the data to a wide range of individuals. This review included trials with participants whose index stroke varied from six days to 13 years before randomisation. It may not be appropriate to consider that the response to treatment is consistent across such mixed populations, as the aetiology (and underlying pathology) of emotionalism may differ between people early on after acute stroke and in the long term. For example, people in the acute phase post‐stroke have recently experienced a potentially life‐threatening event and are coping with the psychological consequences, as well as recovering from the disabling effects of the stroke itself. On the other hand, people who had a stroke several months previously are adjusting to the prospects of long‐term disability and changes in social and financial circumstances, as well as the cumulative effects of cerebrovascular disease or vascular dementia, or both. The natural history of emotionalism after stroke is for spontaneous resolution over a few months, whereas it is reasonable to suppose that it may be a more chronic state in those with chronic cerebrovascular disease. Therefore, since the balance of risks and benefits and the effectiveness of treatment for emotionalism may change with time from the onset of stroke, mixing individuals at very different stages after stroke makes interpretation difficult. Future trials should include homogeneous groups of participants with respect to time from the onset of stroke, or sufficient numbers of participants in the early and late stages after stroke. </p> <p>Defining the disorder of interest is key to the conduct of a clinical trial. A widely agreed definition usually exists for most clinical conditions. However, no such standard definition is available for emotionalism. For example, it does not feature in a clearly defined way in the Diagnostic and Statistical Manual of Mental Disorders (DSM) (<a href="./references#CD003690-bbs2-0046" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IIIR. Washington, DC: American Psychiatric Association, 1987.">APA 1987</a>; <a href="./references#CD003690-bbs2-0047" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association, 1994.">APA 1994</a>; <a href="./references#CD003690-bbs2-0048" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington VA: American Psychiatric Publishing, 2017.">APA 2017</a>), or International Classification of Diseases (ICD) (<a href="./references#CD003690-bbs2-0066" title="World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992.">ICD 10</a>). In the clinical setting, the diagnosis is generally made during interview. The commonly accepted criteria for emotionalism include: 1) sudden onset of crying (and less commonly, laughing); 2) not under usual control (a change in behaviour has occurred); and 3) the crying is not simply an expression of depression or grief. Given the resource‐intensive nature of conducting psychiatric interviews on all participants in clinical trials, we considered it acceptable to determine caseness during a psychiatric interview and to measure frequency and severity using a validated questionnaire. Two standardised scales were used to assess emotionalism: the Pathological Laughter and Crying Scale (PLCS) (<a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>), and the Lawson and Macleod Scale (<a href="./references#CD003690-bbs2-0025" title='LawsonIR , MacLeodRD . The use of imipramine ("Tofranil") and other psychotropic drugs in organic emotionalism. British Journal of Psychiatry1969;115(520):281-5. '>Lawson 1969</a>). An attempt to validate the PLCS was made (<a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>), but neither scale has been externally validated using traditional methods. The 'severity' score on the PLCS includes items recording the quality of crying, not just frequency of occurrence. In the absence of a validated questionnaire, the most appropriate method to diagnose and determine severity of emotionalism is likely to be a simple and easily replicable assessment of the frequency of crying episodes, or laughing episodes (assessing these elements separately), combined with an a priori cut‐off score for entry into the trial. The nature of precipitants should be assessed in separate questions to those assessing frequency of crying and laughing. </p> <p>Emotionalism is known to be confounded by depression (<a href="./references#CD003690-bbs2-0065" title="HouseA , DennisM , MolyneuxA , WarlowC , HawtonK . Emotionalism after stroke. BMJ1989;298(6679):991-4.">House 1989</a>). Tearfulness can be the result of an underlying depressive disorder. The inclusion of participants with depression and emotionalism limits our ability to draw conclusions regarding the treatment of emotionalism alone. While all included trials assessed depression, only two trials reported results (<a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>; <a href="./references#CD003690-bbs2-0007" title="ParikhRM , RobinsonRG , LipseyJR , PriceTR . Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology1989;39 Suppl 1:177. RobinsonR . Additional data provided by author. Data on file2003. RobinsonRG , ParikhRM , LipseyJR , StarksteinSE , PriceTR . Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry1993;150(2):286-93. ">Robinson 1993b</a>). Ideally, future trials should limit inclusion to participants with emotionalism alone, or recruit sufficient participants to allow adjustment for depression in the results, and report the results from all questionnaires administered. </p> <p>The main weakness of this review is the inadequate reporting of some of the trials, which has precluded classification of risk of bias as either low or high risk. This led us to rate some of the trials across the categories as unclear risk of bias, with a small number of trials and participants contributing to most endpoints. </p> </section> <section id="CD003690-sec-0079"> <h3 class="title" id="CD003690-sec-0079">Quality of the evidence</h3> <p>We rated the certainty of evidence for all comparisons using the five GRADE considerations (study limitations, consistency of effect, indirectness, imprecision, and publication bias; <a href="./references#CD003690-bbs2-0089" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Schünemann 2019</a>). We created a summary of findings table. Our rating of the certainty of the evidence ranged from very low to moderate. </p> <p>As is often noted in reviews of the literature, there were several deficiencies in trial methods that further limit our findings. First, most trials (except <a href="./references#CD003690-bbs2-0033" title="OhtomoE , KutsuzawaT , ArakiG , HiraiS , TerashiA , KuzuyaF , et al. Clinical usefulness of tiapride on psychiatric symptoms caused by cerebrovascular disorders: a multi-center double-blind study in comparison with inactive placebo. Rinsho Hyoka1985;13(2):295-332. ">Ohtomo 1985</a>) were small, with only three trials reporting adequate concealment of the randomisation sequence (<a href="./references#CD003690-bbs2-0002" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>). The duration of treatment was short for most trials. Observational studies suggest that many cases of emotionalism resolve over the first months after stroke, so the impact of short‐term therapy may be difficult to assess. Furthermore, case histories report relapse in emotionalism upon withdrawal of treatment, so it would be useful to have information on longer‐term results and relapse rates in future trials. We also included cross‐over trials if the washout period was deemed appropriate. While the benefits and risks of treatment with antidepressants appear to be balanced, only three trials systematically recorded and reported all adverse events in the study, which makes an accurate presentation of the benefits and risks difficult (<a href="./references#CD003690-bbs2-0003" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. BurnsA , RussellE , Stratton-PowellH . A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998. ">Burns 1999</a>; <a href="./references#CD003690-bbs2-0004" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. [PMID: 18648199]Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease2007;23(2-3):103-8. Choi-KwonS , ChoiJM , KwonDW , KimJS . Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke2008;3(Suppl 1):405-6. Choi-KwonS , HanSW , KwonSU , KangDW , ChoiJM , KimJS . Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke2006;37(1):156-61. [PMID: 16306470]Choi-KwonS , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke2009;40(4):e282. ">Choi‐Kwon 2006</a>; <a href="./references#CD003690-bbs2-0005" title="MurrayV , Von ArbinM , AsbergM , BartfaiA , BerggrenA , LandtblomA , et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file2003. MurrayV , Von ArbinM , BartfaiA , BerggrenAL , LandtblomAM , LundmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. [PMID: 15960563]MurrayV , Von ArbinM , VareliusR , OlssonJE , TerentA , SamuelssonM , et al. Sertraline in poststroke depression: a controlled study. Stroke2002;33(1):292. ">Murray 2005</a>). </p> <section id="CD003690-sec-0080"> <h4 class="title">Limitations in study design or execution</h4> <p>Concerning the comparison of pharmaceutical interventions with placebo for diminished tearfulness, we downgraded the certainty of the evidence by one level for strong suspicions of attrition bias, related to the inconsistency in the total number of participants included in the analysis. </p> </section> <section id="CD003690-sec-0081"> <h4 class="title">Inconsistency of results</h4> <p>We downgraded the certainty of the evidence by two levels for the following outcomes: 50% reduction in emotionalism, improved score on the Center for Neurologic Study ‐ Lability Scale (CNS‐LS), Clinician Interview‐Based Impression of Change (CIBIC), and PLCS scores, as there were fewer than 50 participants and only one trial contributing to the analysis for each of these outcomes. </p> </section> <section id="CD003690-sec-0082"> <h4 class="title">Indirectness of evidence</h4> <p>All included trials addressed the main review question (PICO): the effect of pharmaceutical interventions when compared to placebo in reducing the frequency of emotionalism and emotional displays post‐stroke. Thus, we did not downgrade any outcomes in any comparisons for indirectness of evidence. </p> </section> <section id="CD003690-sec-0083"> <h4 class="title">Imprecision</h4> <p>We downgraded the certainty of the evidence for 50% reduction in emotionalism and death by one level owing to wide confidence intervals. </p> </section> <section id="CD003690-sec-0084"> <h4 class="title">Publication bias</h4> <p>We did not downgrade the certainty of the evidence for publication bias in any of the outcomes, as we did not detect publication bias. </p> </section> </section> <section id="CD003690-sec-0085"> <h3 class="title" id="CD003690-sec-0085">Potential biases in the review process</h3> <p>This review has rigorously adhered to the Cochrane methods for performing systematic reviews and their respective updates. During the review process, we have tried to avoid and minimise any biases. We undertook extensive searches of databases and additional resources. We did not apply any language restrictions within the search process. Thus, we believe that we have identified and included all potentially relevant trials in this review. We arranged for any relevant and non‐relevant non‐English language full‐text trials to be translated into English, to finalise the eligibility process. Furthermore, at least two review authors independently extracted and managed the data. </p> </section> <section id="CD003690-sec-0086"> <h3 class="title" id="CD003690-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p>To date, there are no similar meta‐analyses investigating the use of pharmacological interventions in reducing the frequency of emotional displays in people with emotionalism after stroke, with which to compare our findings. Most of the literature in this area are focused on lesion network‐symptom mapping (<a href="./references#CD003690-bbs2-0069" title="KlingbeilJ , WawrzyniakM , StockertA , Brandt M-L, Schneider H-R, MetelmannM , et al. Pathological laughter and crying: insights from lesion network-symptom-mapping. Brain2021;144(10):3264-76.">Klingbeil 2021</a>), clinical and neuroimaging markers (<a href="./references#CD003690-bbs2-0058" title="GillespieDC , HalaiAD , WestRM , DickieDA , WaltersM , BroomfieldNM . Demographic, clinical and neuroimaging markers of post-stroke emotionalism: a preliminary investigation. Journal of the Neurological Sciences2022;436:120229.">Gillespie 2022</a>), and qualitative investigation (<a href="./references#CD003690-bbs2-0055" title="FitzgeraldS , GraceyF , BroomfieldN . Post-stroke emotionalism (PSE): a qualitative longitudinal study exploring individuals' experience with PSE. Disability and Rehabilitation 2021 [Epub ahead of print]. [DOI: 10.1080/09638288.2021.2002439]">Fitzgerald 2021</a>; <a href="./references#CD003690-bbs2-0075" title="McAleeseN , GuzmanA , O'RourkeSJ , GillespieDC . Post-stroke emotionalism: a qualitative investigation. Disability and Rehabilitation2021;43(2):192-200.">McAleese 2021</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003690-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/urn:x-wiley:14651858:media:CD003690:CD003690-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD003690-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_t/tCD003690-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#CD003690-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003690-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/urn:x-wiley:14651858:media:CD003690:CD003690-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003690-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_t/tCD003690-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#CD003690-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003690-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/urn:x-wiley:14651858:media:CD003690:CD003690-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003690-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_t/tCD003690-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#CD003690-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003690-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/urn:x-wiley:14651858:media:CD003690:CD003690-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pharmaceutical interventions versus placebo, Outcome 1: Emotionalism" data-id="CD003690-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_t/tCD003690-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Pharmaceutical interventions versus placebo, Outcome 1: Emotionalism</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/references#CD003690-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003690-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/urn:x-wiley:14651858:media:CD003690:CD003690-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pharmaceutical interventions versus placebo, Outcome 2: Emotionalism: mean scores at end of treatment" data-id="CD003690-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_t/tCD003690-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Pharmaceutical interventions versus placebo, Outcome 2: Emotionalism: mean scores at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/references#CD003690-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003690-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/urn:x-wiley:14651858:media:CD003690:CD003690-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pharmaceutical interventions versus placebo, Outcome 3: Depression: 1. Mean scores at end of treatment" data-id="CD003690-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_t/tCD003690-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Pharmaceutical interventions versus placebo, Outcome 3: Depression: 1. Mean scores at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/references#CD003690-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003690-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/urn:x-wiley:14651858:media:CD003690:CD003690-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pharmaceutical interventions versus placebo, Outcome 4: Depression: 2. Average change in scores between baseline and end of treatment" data-id="CD003690-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_t/tCD003690-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Pharmaceutical interventions versus placebo, Outcome 4: Depression: 2. Average change in scores between baseline and end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/references#CD003690-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003690-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/urn:x-wiley:14651858:media:CD003690:CD003690-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pharmaceutical interventions versus placebo, Outcome 5: Cognitive functioning: mean scores at end of treatment" data-id="CD003690-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_t/tCD003690-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Pharmaceutical interventions versus placebo, Outcome 5: Cognitive functioning: mean scores at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/references#CD003690-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003690-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/urn:x-wiley:14651858:media:CD003690:CD003690-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pharmaceutical interventions versus placebo, Outcome 6: Activities of daily living: 1. Mean scores at end of treatment" data-id="CD003690-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_t/tCD003690-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Pharmaceutical interventions versus placebo, Outcome 6: Activities of daily living: 1. Mean scores at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/references#CD003690-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003690-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/urn:x-wiley:14651858:media:CD003690:CD003690-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pharmaceutical interventions versus placebo, Outcome 7: Adverse events: 1. Death" data-id="CD003690-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_t/tCD003690-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Pharmaceutical interventions versus placebo, Outcome 7: Adverse events: 1. Death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/references#CD003690-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003690-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/urn:x-wiley:14651858:media:CD003690:CD003690-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pharmaceutical interventions versus placebo, Outcome 8: Adverse events: 2. All" data-id="CD003690-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_t/tCD003690-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Pharmaceutical interventions versus placebo, Outcome 8: Adverse events: 2. All </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/references#CD003690-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003690-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/urn:x-wiley:14651858:media:CD003690:CD003690-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pharmaceutical interventions versus placebo, Outcome 9: Adverse events: 3. Leaving the study early (including death)" data-id="CD003690-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_t/tCD003690-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Pharmaceutical interventions versus placebo, Outcome 9: Adverse events: 3. Leaving the study early (including death) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/references#CD003690-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/media/CDSR/CD003690/image_n/nCD003690-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003690-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Pharmaceutical interventions compared to placebo for emotionalism after stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Pharmaceutical interventions compared to placebo for emotionalism after stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> emotionalism after stroke<br/><b>Setting:</b> inpatient<br/><b>Intervention:</b> pharmaceutical interventions<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressants</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Emotionalism (primary outcome) </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% reduction in emotionalism</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>777 per 1000<br/>(7 to 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.26<br/>(0.09 to 0.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improved score on Center for Neurologic Study ‐ Lability Scale (CNS‐LS)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>643 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>926 per 1000<br/>(611 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.20<br/>(0.03 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinician Interview‐Based Impression of Change ‐ improved score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>643 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>926 per 1000<br/>(611 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.20<br/>(0.03 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diminished tearfulness</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>329 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>718 per 1000<br/>(425 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.32<br/>(0.12 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Emotionalism: mean scores at end of treatment ‐ Pathological Laughter and Crying Scale</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8.40 lower<br/>(11.56 lower to 5.24 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(High score = worse emotionalism)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Depression: Mean scores at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.82 lower<br/>(2.14 lower to 0.51 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hamilton Depression Rating Scale; Montgomery Åsberg Depression Rating Scale (high score = more depressed) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Cognitive functioning: Mean scores at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 lower<br/>(3.27 lower to 2.67 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mini‐Mental State Examination (low score = cognitive impairment)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Activities of daily living: 1. Mean scores at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.4 lower<br/>(5.22 lower to 2.42 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Johns Hopkins Functioning Inventory (high score = worse function)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Adverse events: 1. death: at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(2 to 92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.59<br/>(0.08 to 4.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; GRADE: Grades of Recommendation, Assessment, Development and Evaluation; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio; SMD: standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the certainty of evidence as &lt; 50 participants in total, and only 1 study contributed to the analysis.<br/><sup>b</sup>We downgraded the certainty of evidence due to imprecision.<br/><sup>c</sup>We downgraded the certainty of evidence as we rated one of the studies at high risk for attrition bias.<br/><sup>d</sup>Heterogeneity is considerable (I<sup>2</sup> statistic = 84%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Pharmaceutical interventions compared to placebo for emotionalism after stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#CD003690-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003690-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of 'dropout' studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Methods</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003690-bbs2-0008" title="AizawaT , KaseM , KutsuzawaT , HasegawaT , SekimotoH , OmaeT . Clinical evaluation on the effect of cyclandelate in the treatment of cerebrovascular diseases: double-blind comparative placebo-controlled clinical study with cinnarizine as a basic treatment. Rinsho Hyoka1977;5(3):659-86. ">Aizawa 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study design: randomised, parallel design<br/>Number of arms: 2 </p> <p>Arm 1: cyclandelate 900 mg/day + cinnarizine 75 mg/day</p> <p>Arm 2: placebo + cinnarizine 75 mg/day<br/>Analysis: per protocol<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geographical location: Japan</p> <p>Setting: 50 institutes across Japan</p> <p>Number of participants: 378</p> <p>Diagnosis: stroke over 1 month ago</p> <p>Inclusion criteria: 1) inpatients and outpatients who had cerebral infarct, intracranial bleeding, transient cerebral ischaemia, and cerebral arteriosclerosis </p> <p>Exclusion criteria: 1) expectant mothers; 2) with glaucoma, and 3) severe concomitant diseases </p> <p>Age: overall mean age not reported</p> <p>Number of participants included in Arm 1: 188 (68% men, age details unclear)</p> <p>Numbers of participants included in Arm 2: 190 (68% men, age details unclear)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm 1: cyclandelate 900 mg/day and cinnarizine 75 mg/day</p> <p>Arm 2: matched placebo and cinnarizine 75 mg/day</p> <p>Duration: treatment continued for 4 weeks<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD003690-list-0001"> <li> <p>Global improvement rating</p> </li> <li> <p>Improvement rating of subjective symptoms</p> </li> <li> <p>Improvement rating of psychiatric symptoms</p> </li> <li> <p>Improvement rating of neurological symptoms</p> </li> <li> <p>Global utility rating</p> </li> <li> <p>Overall safety rating</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to use: all data (data not presented by 'emotionalism at baseline', unable to exclude people with cerebral arteriosclerosis and transient ischaemic attack) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003690-bbs2-0033" title="OhtomoE , KutsuzawaT , ArakiG , HiraiS , TerashiA , KuzuyaF , et al. Clinical usefulness of tiapride on psychiatric symptoms caused by cerebrovascular disorders: a multi-center double-blind study in comparison with inactive placebo. Rinsho Hyoka1985;13(2):295-332. ">Ohtomo 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study design: randomised, parallel design<br/>Number of arms: 2 </p> <p>Arm 1: tiapride 75 mg/day for 1 week, dose escalation to 150 mg to 225 mg/day for 5 weeks according to clinical response </p> <p>Arm 2: placebo + cinnarizine 75 mg/day<br/>Analysis: per protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geographical location: Japan</p> <p>Setting: unclear</p> <p>Number of participants: 188</p> <p>Diagnosis: cerebral haemorrhage, subarachnoid haemorrhage, cerebral infarction, cerebral apoplexy sequelae, cerebral arteriosclerosis </p> <p>Inclusion criteria: 1) people with cerebral arteriosclerosis</p> <p>Exclusion criteria: 1) severe aphasia, 2) severe dementia, 3) drug dependence, 4) inadequate conditions for the study </p> <p>Age: overall mean age not reported</p> <p>Number of participants included in Arm 1: 141 (54% men, age details unclear)</p> <p>Number of participants included in Arm 2: 147 (61% men, age details unclear)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm 1: tiapride 75 mg/day for 1 week, dose escalation to 150 mg to 225 mg/day for 5 weeks according to clinical response </p> <p>Arm 2: matched placebo</p> <p>Duration: treatment continued for 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD003690-list-0002"> <li> <p>Severity of psychiatric symptoms</p> </li> <li> <p>Activities of daily living</p> </li> <li> <p>Somatic complaints</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to use: all data (data not presented by 'emotionalism at baseline', unable to exclude people with cerebral arteriosclerosis) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003690-bbs2-0024" title="KimJS , LeeEJ , ChangDI , ParkJH , AhnSH , ChaJK , et al. The efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry2017;4(1):33-41. NCT01278498. The preventive effect of escitalopram on depression and related emotional disorders in acute stroke patients. clinicaltrials.gov/ct2/show/NCT01278498 (first received 19 January 2011). ">Kim 2017b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study design: randomised, parallel design<br/>Number of arms: 2 </p> <p>Arm 1: escitalopram 10 mg/day</p> <p>Arm 2: placebo<br/>Analysis: per protocol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geographical location: South Korea</p> <p>Setting: 17 hospitals across South Korea</p> <p>Number of participants: 478</p> <p>Diagnosis: stroke, had an acute ischaemic stroke or intracerebral haemorrhage within the previous 21 days (confirmed by MRI or CT) </p> <p>Inclusion criteria: 1) &gt; 20 years, 2) had an acute ischaemic stroke or intracerebral haemorrhage within the previous 21 days (confirmed by MRI or CT), 3) modified Rankin Scale score &gt; 2 </p> <p>Exclusion criteria: 1) history of diagnosed depression or other psychiatric diseases before the index stroke; 2) severe dementia, 3) aphasia, 4) exhibited strong suicidal thoughts </p> <p>Age: overall mean age not reported</p> <p>Number of participants included in Arm 1: 210 (57% men, mean age 64 (13) years</p> <p>Number of participants included in Arm 2: 195 (65% men, mean age 64 (12) years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm 1: escitalopram 10 mg/day<br/>Arm 2: matched placebo </p> <p>Duration: 12 weeks<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcomes:</p> <p> <ul id="CD003690-list-0003"> <li> <p>Occurrence of moderate or severe depressive symptoms</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD003690-list-0004"> <li> <p>Occurrence of emotional incontinence (Kim's criteria)</p> </li> <li> <p>Anger proneness (modified Spielberger Trait Anger Scale/ National Institutes of Health Stroke Scale scores) </p> </li> <li> <p>Modified Rankin Scale</p> </li> <li> <p>Barthel Index</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to use: all data (data presented by 'emotionalism at baseline' 1 month post‐treatment)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CT: computerised tomography<br/>MRI: magnetic resonance imaging </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of 'dropout' studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/full#CD003690-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003690-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pharmaceutical interventions versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Emotionalism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 50% reduction in emotionalism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.09, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Improved score on Center for Neurologic Study ‐ Lability Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.03, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Clinician Interview‐Based Impression of Change ‐ improved score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.03, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Diminished tearfulness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.12, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Emotionalism: mean scores at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Pathological Laughter and Crying Scale (high score = worse emotionalism)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.40 [‐11.56, ‐5.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Depression: 1. Mean scores at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.82 [‐2.14, 0.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Hamilton Depression Rating Scale (high score = more depressed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.53 [‐2.39, ‐0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Montgomery Åsberg Depression Rating Scale (high score = more depressed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.77, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Depression: 2. Average change in scores between baseline and end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.72, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Hamilton Depression Rating Scale (high score = more depressed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐1.18, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Montgomery Åsberg Depression Rating Scale (high score = more depressed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [‐0.34, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Cognitive functioning: mean scores at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Mini‐Mental State Examination (low score = cognitive impairment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Activities of daily living: 1. Mean scores at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Johns Hopkins Functioning Inventory (high score = worse function)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐5.22, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adverse events: 1. Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 At end of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.08, 4.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Adverse events: 2. All <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Central nervous system events (e.g. confusion, sedation, tremor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.11, 9.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Gastrointestinal effects (e.g. constipation, diarrhoea)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Other events not listed above (e.g. dysuria, eye discomfort)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.26, 95.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.07, 14.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Adverse events: 3. Leaving the study early (including death) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 All dropouts and withdrawals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.38, 3.58]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pharmaceutical interventions versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003690.pub5/references#CD003690-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003690.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003690-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003690-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003690-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003690-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD003690-note-0011">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD003690-note-0009">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD003690-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD003690-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003690-note-0013">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD003690-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003690-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003690\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003690\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003690\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003690\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003690\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003690.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003690.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003690.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003690.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003690.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728978819"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003690.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728978822"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003690.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed1ae3d15f56f',t:'MTc0MDcyODk3OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 